Page last updated: 2024-11-06

oxcarbazepine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxcarbazepine is an anticonvulsant medication used to treat partial seizures in adults and children. It is a derivative of carbamazepine and is thought to work by blocking sodium channels and inhibiting the release of glutamate, a neurotransmitter that plays a role in seizures. Oxcarbazepine is typically taken orally as a tablet or suspension. Common side effects include dizziness, drowsiness, and nausea. Oxcarbazepine is synthesized through a multi-step process that involves the reaction of carbamazepine with an appropriate reagent. It is studied for its potential use in treating other neurological disorders, such as bipolar disorder and trigeminal neuralgia, as well as for its possible anti-inflammatory effects. Oxcarbazepine is an important medication for the treatment of seizures and has been shown to be effective in reducing seizure frequency in many patients. '

Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID34312
CHEMBL ID1068
CHEBI ID7824
SCHEMBL ID35129
MeSH IDM0109945

Synonyms (162)

Synonym
AC-3483
oxcarbazepime
BIDD:GT0078
CHEMBL1068 ,
nsc-758693
chebi:7824 ,
REGID866068
HMS3393O04
AB00393017-14
epliga
spn-804
epilexter
gp-47680
kin-493
MLS000084586 ,
smr000048684
trileptal
oxcarbazepine, >=98% (hplc), solid
10,11-dihydro-10-oxo-5h-dibenz(b,f)azepine-5-carboxamide
oxcarbazepine [inn]
oxcarbazepina [inn-spanish]
5h-dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-10-oxo-
oxcarbazepinum [inn-latin]
SPECTRUM_001675
gp 47680
einecs 249-188-8
BSPBIO_003457
28721-07-5
C07492
oxcarbazepine
MLS000759520
DB00776
ocbz
oxcarbamazepine
9-oxo-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaene-2-carboxamide
trileptal (tn)
oxtellar (tn)
D00533
oxcarbazepine (jan/usp/inn)
SPECTRUM5_001869
NCGC00065934-03
NCGC00065934-02
KBIO2_002155
KBIO2_007291
KBIOGR_001248
KBIO2_004723
KBIO3_002677
KBIOSS_002155
SPECTRUM2_000483
SPECTRUM3_001669
SPBIO_000345
SPECTRUM4_000634
SPECTRUM1504243
NCGC00065934-04
MLS001201742
timox
HMS2051O04
HMS2093E10
HMS2090F13
O0363 ,
10,11-dihydro-10-oxo-5h-dibenzo[b,f]azepine-5-carboxamide
5-oxo-6h-benzo[b][1]benzazepine-11-carboxamide
HMS1922H17
nsc758693
MLS001424025
pharmakon1600-01504243
dtxcid8025703
tox21_110983
dtxsid0045703 ,
cas-28721-07-5
10-oxo-10,11-dihydro-5h-dibenzo[b,f]azepine-5-carboxamide
STK594696
HMS2231B12
CCG-39509
AKOS005516529
oxtellar xr
oxcarbazepine [usan:usp:inn:ban]
unii-vzi5b1w380
oxcarbazepina
oxcarbazepinum
hsdb 7524
vzi5b1w380 ,
nsc 758693
FT-0673414
FT-0630543
NCGC00065934-06
AM20040094
oxcarbazepine [who-dd]
oxcarbazepine [usp monograph]
oxcarbazepine [ep monograph]
oxcarbazepine [mart.]
oxcarbazepine [orange book]
oxcarbazepine [jan]
oxcarbazepine [usan]
oxcarbazepine [usp-rs]
oxcarbazepine [hsdb]
oxcarbazepine [mi]
oxcarbazepine [vandf]
S1391
gtpl7254
HMS3369J22
CS-1869
HY-B0114
AB00393017-12
10,11-dihydro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide
5-carbamoyl-10-oxo-10,11-dihydro-5h-dibenz[b,f]azepine
10-oxo-10,11-dihydro-5h-dibenz(b,f)azepin-5-carboxamide
NC00088
SCHEMBL35129
NCGC00065934-05
tox21_110983_1
KS-5197
cid_34312
bdbm34179
MLS006011855
W-107033
10,11-dihydro-10-oxo-5h-dibenzo(z)[b,f]azepine-5-carboxamide
10,11-dihydro-10-oxo-5h-dibenz[b,f]azepin-5-carbonsaeureamid
5h-dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo-
10-oxo-10,11-dihydro-5h-dibenzo[b,f]azepine-5-carboxamide #
AB00393017_15
AB00393017_16
OPERA_ID_818
mfcd00865307
oxacarbazepine
SR-01000612612-6
SR-01000612612-4
sr-01000612612
oxcarbazepine, analytical standard
oxcarbazepine, united states pharmacopeia (usp) reference standard
HMS3657O11
oxcarbazepine, pharmaceutical secondary standard; certified reference material
oxcarbazepine, european pharmacopoeia (ep) reference standard
SBI-0206772.P001
HMS3713I10
SW197468-3
gp-47-680
10-oxo carbazepine; oxecarb; 10,11-dihdyro-10-oxo-5h-dibenz[b,f]azepine-5-carboxamide
BCP28260
Q176301
BRD-K04196797-001-12-9
A13943
BCP33398
HMS3884K13
M06310
oxcarbazepine- bio-x
BO164187
9-oxo-2-azatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxamide
EN300-123538
oxcarbazepina (inn-spanish)
oxcarbazepine (usp-rs)
oxcarbazepine (mart.)
n03af02
oxcarbazepinum (inn-latin)
10-oxo-10,11-dihydro-5h-dibenzo(b,f)azepine-5-carboxamide
oxcarbazepine (usp monograph)
oxcarbazepine (ep monograph)
oxtellar
oxcarbazepine (usan:usp:inn:ban)
Z1551967555
SY052973
oxcarbazepine, 1mg/ml in acetonitrile

Research Excerpts

Overview

Oxcarbazepine (OXC) is a frequently prescribed antiepileptic drug for managing focal and generalized seizures. It is a keto-analogue of carbamazepine, an established AED, and can be used as an add-on treatment for drug-resistant epilepsy.

ExcerptReferenceRelevance
"Oxcarbazepine (OXC) is an antiepileptic drug. "( Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
Czendlik, C; Flesch, G; Lloyd, P; Renard, D, 2011
)
2.07
"Oxcarbazepine (OXC) is a frequently prescribed antiepileptic drug for managing focal and generalized seizures. "( Thermoresponsive Gel-loaded Oxcarbazepine Nanosystems for Nose- To-Brain Delivery: Enhanced Antiepileptic Activity in Rats.
Abou-Taleb, BA; El-Ganainy, SO, 2023
)
2.65
"Oxcarbazepine is a keto-analogue of carbamazepine, an established AED, and can be used as an add-on treatment for drug-resistant epilepsy."( Oxcarbazepine add-on for drug-resistant focal epilepsy.
Atim-Oluk, M; Bresnahan, R; Marson, AG, 2020
)
2.72
"Oxcarbazepine is an analog of carbamazepine designed to minimize effects from the hepatic P450 metabolic enzymes."( A Case Series of Patients With Central Hypothyroidism From Oxcarbazepine Therapy.
Lao, AJ; Schweiger, BM; Tavyev, J, 2021
)
1.59
"Oxcarbazepine is a second-generation anti-epileptic drug approved for use in pediatric patients, and eslicarbazepine acetate is a newer generation drug used as adjunctive therapy and monotherapy for partial-onset (focal) seizures."( Retrospective Analysis of Pediatric and Adult Populations Using an LC-MS/MS Method for Oxcarbazepine/Eslicarbazepine Metabolite.
Johnson-Davis, KL; Kroner, GM; Thomas, RL, 2021
)
1.57
"Oxcarbazepine (OXC) is an antiepileptic drug. "( Chronic oxcarbazepine intoxication in a patient with primary antiphospholipid syndrome on maintenance haemodialysis.
Artim-Esen, B; Dirim, AB; Inanc, M; Mirioglu, S; Oguz, E; Yazici, H; Yesilot, N, 2022
)
2.6
"Oxcarbazepine is a cytochrome P450 (CYP) 3A4 inducer, which is structurally similar to carbamazepine. "( Possible Oxcarbazepine Inductive Effects on Aripiprazole Metabolism: A Case Report.
de Leon, J; Loveland, JG; McGrane, IR, 2018
)
2.34
"Oxcarbazepine is a second-generation antiepileptic drug that is used to treat partial seizures. "( In Utero Oxcarbazepine Exposure and Neonatal Abstinence Syndrome: Case Report and Brief Review of the Literature.
Chen, CY; Cui, YM; Feng, Q; Li, X; Ma, LY; Wu, PH; Zhou, Y, 2017
)
2.31
"Oxcarbazepine is an antiepileptic drug with an activity mostly due to its monohydroxy derivative metabolite (MHD). "( Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
Chiron, C; Comets, E; Dulac, O; Jullien, V; Pons, G; Rey, E; Rodrigues, C, 2017
)
2.18
"Oxcarbazepine is an anticonvulsant drug closely related to carbamazepine."( Oxcarbazepine for neuropathic pain.
Chen, N; He, L; Wu, F; Yang, M; Zhou, M; Zhu, C, 2017
)
2.62
"Oxcarbazepine is an antiepileptic drug (AED) commonly used as a first-line treatment option for focal epilepsy. "(
Alzaidi, Y; Chadwick, L; Kim, H; Manzi, S; Picker, J; Poduri, A, 2018
)
1.92
"Oxcarbazepine (OXC) is a drug that has a similar structure of carbamazepine."( Association between HLA-B*15:02 and oxcarbazepine-induced cutaneous adverse reaction: a meta-analysis.
Liu, Y; Nie, X; Wang, X; Yu, Y; Zhao, L, 2018
)
1.48
"Oxcarbazepine (OXC) is an antiepileptic drug metabolised to active 10-monohydroxy derivative (MHD) following oral administration. "( Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
Jiao, Z; Li, XW; Lin, WW; Lin, XH; Rao, X; Wang, CL; Zeng, DY; Zhang, J, 2019
)
2.24
"Oxcarbazepine is a carbamazepine pre-drug with less drug interactions. "( Patient Survival After Acute Voluntary Poisoning With a Huge Dose of Oxcarbazepine and Olanzapine.
Eleftheriotis, G; Galopoulos, D; Kalogera, V; Loupa, C; Malios, I; Marathonitis, G; Meimeti, E, 2018
)
2.16
"Oxcarbazepine (OXC) is a widely used antiepileptic drug whose effect mainly depends on its active metabolite 10-hydroxycarbazepine (MHD). "( Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy.
Chen, CY; Cui, YM; Wu, Y; Yang, T; Zhao, X; Zhou, Y, 2019
)
2.21
"Oxcarbazepine is an anticonvulsant drug closely related to carbamazepine and is reportedly better tolerated."( Oxcarbazepine for neuropathic pain.
Chen, N; He, L; Wu, F; Yang, M; Zhou, M; Zhu, C, 2013
)
2.55
"Oxcarbazepine is an antiepileptic agent that has been used during pregnancy, although its safety during pregnancy has not been sufficiently established. "( In utero oxcarbazepine and a withdrawal syndrome, anomalies, and hyponatremia.
Klinger, G; Merlob, P; Rolnitsky, A, 2013
)
2.25
"Oxcarbazepine is a second-generation antiepileptic drug indicated as monotherapy or adjunctive therapy in the treatment of partial seizures or generalized tonic-clonic seizures in adults and children. "( Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study.
Alexandre, V; Coelho, EB; de Jesus Antunes, N; Della Pasqua, O; Lanchote, VL; Takayanagui, OM; Tozatto, E; Wichert-Ana, L, 2013
)
2.21
"Oxcarbazepine (OXC) is an effective anticonvulsant used for treatment of partial and secondarily generalized seizures. "( Use of oxcarbazepine for treatment of refractory status epilepticus.
Berning, S; Kellinghaus, C; Stögbauer, F, 2014
)
2.3
"Oxcarbazepine (OXC) is a new anti-epileptic agent that has been used recently for childhood epilepsies such as VPA."( Ciliary body toxicities of systemic oxcarbazepine and valproic acid treatments: electron microscopic study.
Aktaş, Z; Cansu, A; Erdoğan, D; Göktaş, G; Kaplanoğlu, GT; Karaca, EE; Serdaroğlu, A; Seymen, CM, 2015
)
1.41
"Oxcarbazepine is a new antiepileptic drug. "( [Adverse effects of oxcarbazepine].
Fang, S; Gong, ZC, 2015
)
2.18
"Oxcarbazepine (OXC) is a 10-keto analogue of carbamazepine used in patients with partial and secondary generalized seizures. "( Thirteen years of oxcarbazepine exposures reported to US poison centers: 2000 to 2012.
Burns, G; Essing-Spiller, SJ; Spiller, HA; Strauch, J, 2016
)
2.21
"Oxcarbazepine (OXC) is a widely used antiepileptic drug for the treatment of partial seizures that was developed through structural variation of carbamazepine. "( HLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption.
Byun, JI; Chu, K; Jang, IJ; Jeon, D; Jung, KH; Jung, KY; Kim, TJ; Lee, SK; Lee, ST; Lim, JA; Moon, J; Park, KI; Sunwoo, JS; Yu, KS, 2016
)
2.13
"Oxcarbazepine (Trileptal) is an antiepileptic drug used as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children. "( Bioequivalence of oxcarbazepine oral suspension vs. film-coated tablet in healthy Chinese male subjects.
Appel-Dingemanse, S; Hu, P; Jiang, J; Merz, M; Souppart, C; Yin, Q, 2008
)
2.12
"Oxcarbazepine is a drug that is approved as monotherapy for the treatment of partial seizures and generalized tonic-clonic seizures."( Effect of oxcarbazepine on sleep architecture.
Ayala-Guerrero, F; González, V; Hernandez, M; Mexicano, G, 2009
)
1.48
"Oxcarbazepine is a newer antiepileptic drug related to carbamazepine that is claimed to be better tolerated."( Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures.
Koch, MW; Polman, SK, 2009
)
2.52
"Oxcarbazepine is an anticonvulsant drug that has been explored as a novel therapeutic agent to treat neuropathic pain in humans. "( Caffeine reverses antinociception by oxcarbazepine by inhibition of adenosine A1 receptors: insights using knockout mice.
Fredholm, BB; Reid, AR; Sawynok, J, 2010
)
2.08
"Oxcarbazepine is an analogue of carbamazepine, used for the treatment of partial seizure with or without secondary generalization. "( [Therapeutic drug monitoring of oxcarbazepine].
Bentué-Ferrer, D; Bouquié, R; Dailly, E,
)
1.86
"Oxcarbazepine is an antiepileptic drug widely used for the treatment of neuropathic pain. "( The conduction block produced by oxcarbazepine in the isolated rat sciatic nerve: a comparison with lamotrigine.
Bozdemir, H; Gunay, I; Guven, M; Kahraman, I; Koc, F; Sarica, Y, 2011
)
2.09
"Oxcarbazepine is a representative molecule for a new class of anticonvulsant drugs that can treat alcohol dependence in addition to other disorders. "( Pharmaco-EEG-based assessment of the interaction between ethanol and oxcarbazepine.
Czarnecka, E; Pietrzak, B,
)
1.81
"Oxcarbazepine which is a frequently used new antiepileptic drug in childhood epilepsy may modify nitric oxide levels and lipid peroxidation."( Effects of epilepsy and antiepileptic drugs on nitric oxide, lipid peroxidation and xanthine oxidase system in children with idiopathic epilepsy.
Arhan, E; Kurt, N; Kutsal, E; Ozcelik, A; Ozturk, B; Ozturk, HS; Serdaroglu, A; Sevinc, N, 2011
)
1.09
"Oxcarbazepine is a second-generation antiepileptic drug (AED) with proven efficacy in managing partial epileptic seizures, with or without secondary generalization, in adults and children. "( Rationale and evidence for the use of oxcarbazepine in neuropathic pain.
Carrazana, E; Mikoshiba, I, 2003
)
2.03
"Oxcarbazepine is an antiepileptic drug with a chemical structure similar to carbamazepine, but with different metabolism. "( Clinical pharmacokinetics of oxcarbazepine.
Korn-Merker, E; May, TW; Rambeck, B, 2003
)
2.05
"Oxcarbazepine is a recently introduced AED that is effective in treating epilepsy and has an improved side-effect profile compared to existing therapies."( Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig.
Bevan, S; Fox, A; Gentry, C; Kesingland, A; Patel, S, 2003
)
1.3
"Oxcarbazepine (OXC) is a new drug chemically related to CBZ."( Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies.
Baldy-Moulinier, M; Crespel, A; Gelisse, P; Genton, P; Kuate, C; Pesenti, A, 2004
)
1.35
"Oxcarbazepine appears to be a promising alternative monotherapeutic approach for patients affected by PHN."( Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin.
Auletta, C; Brogi, A; Brogi, F; Criscuolo, S; Lippi, S, 2005
)
3.21
"Oxcarbazepine (OZC) is a second-generation antiepileptic drug (AED) that also may be used as a mood stabilizer. "( Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine.
Cacciola, M; D'Arrigo, C; La Torre, D; Migliardi, G; Pacetti, M; Rosaria Muscatello, M; Spina, E; Zoccali, R, 2005
)
2
"Oxcarbazepine is an antiepileptic drug (AED) indicated for use as monotherapy and add-on therapy in adults and children 4 years of age and older. "( Amelioration of erectile dysfunction following a switch from carbamazepine to oxcarbazepine: recent clinical experience.
Sachdeo, R; Sathyan, RR, 2005
)
2
"Oxcarbazepine (OCBZ) is a keto analog of carbamazepine (CBZ) and may have similar analgesic properties to CBZ, but studies on its effects in neuropathic pain conditions are rare. "( The suppressive effects of oxcarbazepine on mechanical and cold allodynia in a rat model of neuropathic pain.
Jang, Y; Kim, ES; Lee, J; Moon, DE; Park, SS, 2005
)
2.07
"Oxcarbazepine is a newer AED that is indicated for use as monotherapy and adjunctive therapy in children (United States 4 years of age, Europe 6 years of age) with partial epilepsy."( Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience.
Bourgeois, BF; D'Souza, J, 2005
)
1.32
"Oxcarbazepine is a analogue of carbamazepine with anticonvulsant and analgesic activity. "( [Oxcarbazepine-induced localized penile edema].
Moussatou, V; Papadakis, P; Rallis, E; Theodoridis, A; Verros, C, 2005
)
2.68
"Oxcarbazepine is an antiepileptic drug widely used to treat partial seizures in children and adults. "( Possible precipitation of myoclonic seizures with oxcarbazepine.
Holmes, GL; Kaddurah, AK, 2006
)
2.03
"Oxcarbazepine (OXC; Timox) is a new antiepileptic drug (AED) chemically related to carbamazepine (CBZ), with comparable efficacy but superior safety according to controlled clinical trials. "( [Oxcarbazepine in the treatment of epilepsy].
Freidel, M; Krause, E; Kuhn, K; Peper, R; Vogel, H, 2007
)
2.69
"Oxcarbazepine is a newer antiepileptic drug that is rapidly converted to a monohydroxy derivative, the active compound."( Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension.
Clemens, PL; Cloyd, JC; Kriel, RL; Remmel, RP, 2007
)
1.29
"Oxcarbazepine (OXC) is a keto-congener of carbamazepine, which has fewer side effects and drug interactions. "( Oxcarbazepine in bipolar disorder: a critical review of the literature.
Bria, P; Conte, G; Di Nicola, M; Janiri, L; Martinotti, G; Mazza, M; Mazza, S; Pozzi, G; Taranto, C, 2007
)
3.23
"Oxcarbazepine is an antiepileptic drug that has been approved by the US FDA and is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children aged over 4 years. "( Oxcarbazepine in the treatment of bipolar and schizoaffective disorders.
Bernabarre, A; Bernardo, M; Leighton, C; Popova, E; Vieta, E, 2007
)
3.23
"Oxcarbazepine (OXC) is an anitepileptic medication recently approved as monotherapy for partial onset seizure and demonstrated to be useful in the treatment of several neuropathic pain. "( Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study.
Mancardi, GL; Restivo, D; Solaro, C; Tanganelli, P, 2007
)
3.23
"Oxcarbazepine is a commonly used antiepileptic and mood stabilizer medication with a considerably good safety profile. "( Oxcarbazepine-induced hemolytic anemia in a geriatric patient.
Abrar, M; Chaudhry, MM; Mendoza, C; Mutahir, K,
)
3.02
"Oxcarbazepine is a poorly water-soluble (0.083 mg/ml) anti-epileptic drug according to the BCS system (class II) and its dissolution is rate-limiting step for its absorption. "( Tablet formulation studies on an oxcarbazepine-beta cyclodextrin binary system.
Chotai, NP; Patel, MP; Patel, NV, 2008
)
2.07
"Oxcarbazepine (OCBZ) is a new antiepileptic drug (AED) structurally related to carbamazepine (CBZ) but differing in several important aspects, notably metabolism and induction of metabolic pathways. "( Clinical pharmacology and pharmacokinetics of oxcarbazepine.
Dieterle, W; Flesch, G; Lloyd, P, 1994
)
1.99
"Oxcarbazepine (OCBZ) is a keto homologue of carbamazepine (CBZ) with a completely different metabolic profile."( Oxcarbazepine: pharmacokinetic interactions and their clinical relevance.
Albani, F; Baruzzi, A; Riva, R, 1994
)
2.45
"Oxcarbazepine appears to be an effective and well-tolerated drug for localization-related early childhood epilepsy."( Oxcarbazepine in the treatment of early childhood epilepsy.
Gaily, E; Granström, ML; Liukkonen, E, 1997
)
2.46
"Oxcarbazepine appears to be an effective and well-tolerated drug for children and adolescents with intellectual disability and epilepsy."( Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability.
Gaily, E; Granström, ML; Liukkonen, E, 1998
)
2.46
"Oxcarbazepine is a new antiepileptic drug which in humans acts as a prodrug to its central nervous system-active metabolite 10-hydroxycarbazepine. "( Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects.
Bialer, M; Perucca, E; Sintov, A; Volosov, A; Xiaodong, S; Yagen, B, 1999
)
1.97
"Oxcarbazepine is a highly efficacious antiepileptic drug which has very few side effects and has been poorly investigated as to its effects during human and animal gestation."( [Pre-embryo development in rats treated with oxcarbazepine in the first four days after insemination].
de O Guerra, M; de Oliveira, LE; Peters, VM,
)
1.83
"Oxcarbazepine is a new antiepileptic drug (AED) that has been registered in more than 50 countries worldwide since 1990 and recently received approval in the United States and the European Union. "( Oxcarbazepine in the treatment of epilepsy.
Glauser, TA, 2001
)
3.2
"Oxcarbazepine (OXC) is a new antiepileptic drug derived from carbamazepine (CBZ). "( [Oxcarbazepine].
Arroyo, S, 2001
)
2.66
"Oxcarbazepine is a potent antineuralgic drug with very good acceptability and tolerability."( Long-term cohort study comparing medical (oxcarbazepine) and surgical management of intractable trigeminal neuralgia.
Patsalos, PN; Zakrzewska, JM, 2002
)
1.3
"Oxcarbazepine (OXC) is a new anti-epileptic agent structurally related to carbamazepine (CBZ). "( Effects of oxcarbazepine and carbamazepine on the central nervous system: computerised analysis of saccadic and smooth-pursuit eye movements.
Gangemi, PF; Massi, S; Messori, A; Monza, GC; Parigi, A; Valenza, T; Zaccara, G, 1992
)
2.12
"Oxcarbazepine is a new anticonvulsant, currently undergoing clinical trials. "( Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant.
Dickinson, RG; Dunstan, PR; Eadie, MJ; Hooper, WD; Pendlebury, SC, 1987
)
3.16
"Oxcarbazepine is an anti-epileptic drug, which is almost completely metabolized by cytosolic enzymes in the liver to the active 10-monohyroxy metabolite (MHD) following oral administration. "( Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
Bouillon, T; Fink, M; Hirota, T; Sugiyama, I; Suzuki, H; Yamaguchi, M, 2015
)
2.09
"Oxcarbazepine (OXC) is a promising alternative for patients who cannot tolerate carbamazepine. "( Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles.
Guo, J; He, N; Li, BM; Liao, JX; Liao, WP; Liu, XR; Min, FL; Ou, YM; Shi, YW; Zhou, JH, 2012
)
2.11
"Oxcarbazepine is an FDA approved anticonvulsant medication that has also been used clinically as a treatment for chronic neuropathic pain. "( Symptomatic hyponatremia in patients on oxcarbazepine therapy for the treatment of neuropathic pain: two case reports.
Adkoli, S, 2003
)
2.03
"Oxcarbazepine appears to be an important alternative therapeutic approach for patients affected by TN."( Oxcarbazepine monotherapy in carbamazepine-unresponsive trigeminal neuralgia.
Anciones, B; Aragón, E; Arrojo, FG; Dorado, R; Gomez-Arguelles, JM; Herrera, A; Huete, CR; Sepulveda, JM; Terrón, C, 2008
)
2.51

Effects

Oxcarbazepine has efficacy as an add-on treatment in patients with drug-resistant partial epilepsy, both in adults and children. It has been reported to precipitate myoclonic, generalised tonic-clonic, absence, and complex partial seizures. Oxcarbazapine has a low propensity to inhibit or induce oxidative enzymes.

ExcerptReferenceRelevance
"Oxcarbazepine has a low propensity to inhibit or induce oxidative enzymes. "( Pharmacokinetic drug interactions in children taking oxcarbazepine.
D'souza, J; Hossain, M; Milosavljev, S; Sallas, WM, 2003
)
2.01
"Oxcarbazepine has been reported to be efficacious in the treatment of neuropathic pain, but evidence from randomised controlled trials (RCTs) is conflicting."( Oxcarbazepine for neuropathic pain.
Chen, N; He, L; Wu, F; Yang, M; Zhou, M; Zhu, C, 2017
)
2.62
"Oxcarbazepine has been reported to be efficacious in the treatment of neuropathic pain."( Oxcarbazepine for neuropathic pain.
Chen, N; He, L; Wu, F; Yang, M; Zhou, M; Zhu, C, 2013
)
2.55
"Oxcarbazepine has been effective in managing the kinesigenic form of this disorder; however, its use has never been reported in PNKD to our knowledge."( Effective Treatment of Paroxysmal Nonkinesigenic Dyskinesia With Oxcarbazepine.
Jabbari, B; Kumar, A; Szekely, A,
)
1.09
"Oxcarbazepine has efficacy as an add-on treatment in patients with drug-resistant partial epilepsy, both in adults and children. "( WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy.
Castillo, SM; Schmidt, DB; Shukralla, A; White, S, 2016
)
2.27
"Oxcarbazepine has been reported to precipitate myoclonic, generalised tonic-clonic, absence, and complex partial seizures, and carbamazepine to precipitate absences, myoclonic seizures and spasms. "( Possible induction of West syndrome by oxcarbazepine therapy in a patient with complex partial seizures.
Mikati, MA; Singh, P; Veerapandiyan, A, 2012
)
2.09
"Oxcarbazepine has a low propensity to inhibit or induce oxidative enzymes. "( Pharmacokinetic drug interactions in children taking oxcarbazepine.
D'souza, J; Hossain, M; Milosavljev, S; Sallas, WM, 2003
)
2.01
"Oxcarbazepine (OCBZ) has been accepted for registration as a first-line antiepileptic drug (AED) in several countries. "( Clinical development outlook of oxcarbazepine.
Schwabe, S, 1994
)
2.01
"Oxcarbazepine has been proven to be a promising new antiepileptic drug for the treatment of human epilepsy. "( Pharmacokinetics of oxcarbazepine in the dog.
Frey, HH; Schicht, S; Wigger, D, 1996
)
2.06
"Oxcarbazepine (OXC) has been licensed as monotherapy and add-on treatment in epilepsy patients with partial seizures with or without secondarily generalized seizures (PS) and generalized tonic-clonic seizures without partial onset (GTCS). "( A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy.
Brodie, MJ; Christe, W; Krämer, G; Moore, A; Pohlmann, H; Steinhoff, BJ; Vigonius, U, 1997
)
2
"Oxcarbazepine has been reported to be a preferable antiepileptic drug, when compared to carbamazepine with respect to its effects on lipid metabolism, especially cholesterol, high-density lipoproteins, and low-density lipoproteins."( Oxcarbazepine versus carbamazepine treatment and induction of serum lipid abnormalities.
Papacostas, S, 2000
)
2.47
"Oxcarbazepine has efficacy as an add-on treatment in patients with drug-resistant partial epilepsy, both in adults and children. "( Oxcarbazepine add-on for drug-resistant partial epilepsy.
Castillo, S; Schmidt, DB; White, S, 2000
)
3.19
"Oxcarbazepine (OXC) has been licensed for monotherapy and add-on therapy of focal epilepsy in Germany since February 2000. "( [Ad hoc change from carbamazepine to oxcarbazepine--effectiveness and tolerance. A retrospective analysis].
Homberg, V; Kowalik, A; Schulze-Bonhage, A, 2001
)
2.03
"Oxcarbazepine also has approval for monotherapy in partial seizures."( Newer therapies in the drug treatment of epilepsy.
Biederman, TS; McAuley, JW; Moore, JL; Smith, JC, 2002
)
1.04

Actions

Oxcarbazepine may increase the responder rate for 50% or greater reduction in seizure frequency compared to control treatment (RR 1.80, 95% CI 1.27 to 2.56) Oxcarbazapine did not suppress spreading depression either after a single dose or after daily treatment for 5 weeks.

ExcerptReferenceRelevance
"Oxcarbazepine may increase the responder rate for 50% or greater reduction in seizure frequency compared to control treatment (RR 1.80, 95% CI 1.27 to 2.56; random-effects model; 6 studies; low-certainty evidence)."( Oxcarbazepine add-on for drug-resistant focal epilepsy.
Atim-Oluk, M; Bresnahan, R; Marson, AG, 2020
)
2.72
"Oxcarbazepine, which plays the mechanism of the sodium channel blockers, has a more significant effect than levetiracetam, which has no mechanism of the sodium channel blockers in self-limited familial infantile epilepsy."( Different experiences of two PRRT2-associated self-limited familial infantile epilepsy.
Fang, S; Hu, Y; Li, F; Li, X; Lin, Z; Liu, Z; Zhao, Q; Zheng, F, 2020
)
1.28
"Oxcarbazepine is used in lower doses than recommended and the dosing is not adjusted for weight. "( [Utilization of carbamazepine and oxcarbazepine in pediatric patients with partial epilepsy in Spain. An observational study].
Carreño, M; Rufo Campos, M,
)
1.85
"Oxcarbazepine did not suppress spreading depression either after a single dose or after daily treatment for 5 weeks. "( Oxcarbazepine does not suppress cortical spreading depression.
Ayata, C; Dileköz, E; Hoffmann, U; Kudo, C, 2011
)
3.25
"Oxcarbazepine, however, can cause oral contraceptive pill failure."( Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine.
Binnie, CD; Elwes, RD, 1996
)
1.23
"Oxcarbazepine did not cause any statistically significant slowing of nerve conduction."( Comparison of the effects of carbamazepine and oxcarbazepine on peripheral nerve conduction.
Danner, R; Hallikainen, E; Keränen, T; Partanen, J; Reinikainen, K; Riekkinen, P,
)
1.11

Treatment

Oral treatment with oxcarbazepine (100 mg/kg) produced an increment in total sleep time throughout the recording period. Treatment over 6 months does not display any differential effects on cognitive function and intelligence in children and adolescents with newly diagnosed partial seizures.

ExcerptReferenceRelevance
"Oxcarbazepine treatment was terminated after the intravenous immunoglobulin treatment."( Hemophagocytic lymphohistiocytosis associated with oxcarbazepine.
Acıpayam, C; Güneş, H; Kırık, S; Kırık, Y; Sarışık, N; Yurttutan, S, 2019
)
1.49
"Oxcarbazepine treatment over 6 months does not display any differential effects on cognitive function and intelligence in children and adolescents with newly diagnosed partial seizures relative to standard antiepileptic drug therapy. "( The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures.
Aldenkamp, AP; Campistol, J; Daehler, M; Donati, F; Gobbi, G; Rapatz, G; Sturm, Y, 2007
)
2.09
"Oxcarbazepine treatment was being administered to 52% (mean dose: 1134.4 mg/day) and 48% were receiving carbamazepine (mean dose: 876.3 mg/day)."( [An observational study of the patterns of carbamazepine and oxcarbazepine utilisation in adult patients with partial epilepsy in Spain].
Carreno-Martinez, M; Rufo-Campos, M,
)
1.09
"Treatment with oxcarbazepine was associated with an increased treatment withdrawal rate compared to control (RR 1.75, 95% CI 1.44 to 2.13; fixed-effect model; 6 studies; moderate-certainty evidence)."( Oxcarbazepine add-on for drug-resistant focal epilepsy.
Atim-Oluk, M; Bresnahan, R; Marson, AG, 2020
)
2.34
"Treatment with oxcarbazepine resulted in a substantial reduction in the frequency and severity of episodes."( Effective Treatment of Paroxysmal Nonkinesigenic Dyskinesia With Oxcarbazepine.
Jabbari, B; Kumar, A; Szekely, A,
)
0.71
"Treatment with oxcarbazepine was seen to produce a statistically significant reduction in craving and impulsivity after 4, 8 and 12 weeks, with respect to baseline measures at the start of treatment."( [Efficacy of oxcarbazepine treatment in patients diagnosed with cocaine abuse/dependence].
Castillo Aguilella, A; Llopis Llácer, JJ, 2008
)
1.05
"Oral treatment with oxcarbazepine (100 mg/kg) produced an increment in total sleep time throughout the recording period."( Effect of oxcarbazepine on sleep architecture.
Ayala-Guerrero, F; González, V; Hernandez, M; Mexicano, G, 2009
)
1.07
"Treatment with oxcarbazepine was initiated at 150 mg/day, and the daily dose was doubled on a weekly basis and titrated to tolerability over 4 weeks, up to 1200 mg/day."( Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy.
Beydoun, A; Carrazana, EJ; Kobetz, SA,
)
0.85
"Treatment with oxcarbazepine was relatively well tolerated; dizziness, sedation and nausea were the most frequently reported adverse effects."( A pilot clinical trial of oxcarbazepine in adults with attention-deficit hyperactivity disorder.
Davids, E; Gastpar, M; Kis, B; Specka, M, 2006
)
0.97

Toxicity

The overall adverse event profile was found to be superior for oxcarbazepine. A significantly greater number of patients in divalproex group experienced one or more adverse drug events. The results of our study are consistent with clinical observations.

ExcerptReferenceRelevance
" Adverse effects of antiepileptic treatment may affect the patient's quality of life to an even greater extent than the occurrence of seizures."( Adverse effects of established and new antiepileptic drugs: an attempted comparison.
Gram, L; Rogvi-Hansen, B, 1995
)
0.29
" There was no significant difference between the two groups with respect to premature discontinuation due to adverse events."( Safety and tolerability of oxcarbazepine in elderly patients with epilepsy.
Beydoun, A; D'Souza, J; Kutluay, E; McCague, K, 2003
)
0.62
" OXC was well tolerated, with 13% of patients exiting because of adverse events."( Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy.
Beydoun, A; D'Souza, J; Kutluay, E; McCague, K; Sachdeo, RC, 2003
)
0.58
"The incidence of adverse events, which were mild in severity, was similar between all treatment groups, including the placebo group."( Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans.
Almeida, L; Soares-da-Silva, P, 2003
)
0.32
" All adverse events were mild in severity, except for 1 case of somnolence of moderate severity, which occurred in a subject receiving 1200 mg BIA 2-093."( Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.
Almeida, L; Soares-da-Silva, P, 2004
)
0.32
"Newly designed antiepileptic drugs (AEDs) are being evaluated for their efficacy in preventing seizures and for their toxic profiles."( Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093.
Ambrósio, AF; Araújo, IM; Carvalho, AP; Carvalho, CM; Leal, EC; Malva, JO; Soares-da-Silva, P; Verdasca, MJ, 2004
)
0.53
"In all parameters assayed, OXC was more toxic than the other AEDs used."( Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093.
Ambrósio, AF; Araújo, IM; Carvalho, AP; Carvalho, CM; Leal, EC; Malva, JO; Soares-da-Silva, P; Verdasca, MJ, 2004
)
0.53
" The most common adverse events (10%) in the CDP were headache (32."( Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience.
Bourgeois, BF; D'Souza, J, 2005
)
0.6
" OXC was well tolerated, with the most common adverse events consisting of vertigo, tremor, somnolence, hypotension and nausea."( Oxcarbazepine is effective and safe in the treatment of neuropathic pain: pooled analysis of seven clinical studies.
Arghetti, S; Bianconi, C; Cavallotti, G; Di Palma, F; Galimberti, V; Jann, S; Magenta, P; Osio, M; Siciliano, G; Sterlicchio, M; Sterzi, R, 2005
)
1.77
"To investigate the relationship between the serum concentration of the mono-hydroxy-derivative (MHD) of oxcarbazepine (OXC) and adverse effects (AEs) in epileptic patients on high-dose OXC therapy."( Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy.
Bilo, L; Di Nocera, P; Fasiello, C; Italiano, D; Pisani, F; Ruosi, P; Striano, P; Striano, S, 2006
)
0.75
" The authors present the cases of two children who developed relatively uncommon adverse effects to new anticonvulsant medications, including metabolic acidosis with topiramate and hyponatremia with oxcarbazepine."( New anticonvulsants--new adverse effects.
Tebb, Z; Tobias, JD, 2006
)
0.52
" The most frequent (>10%) adverse events were dizziness, nausea, headache, somnolence, and fatigue."( Efficacy, safety, and tolerability of oxcarbazepine monotherapy.
Barkley, GL; Blakeslee, M; D'Souza, J; Ingenito, A; Martinez, W; McCague, K, 2006
)
0.6
" Safety was assessed by monitoring adverse events (AEs), serious AEs (SAEs), hematology, blood chemistry, urinalysis values, and vital signs."( Long-term safety and tolerability of oxcarbazepine in painful diabetic neuropathy.
Alarcón, F; Beydoun, S; Mangat, S; Wan, Y, 2007
)
0.61
"The aim of this study was to investigate the relationships between oxcarbazepine (OXC) dosage, metabolite mono-hydroxy-derivative (MHD) serum concentrations, number of concomitant antiepileptic drugs, age and incidence of adverse events (AEs) in epileptic patients."( Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy.
Foschi, N; Ortenzi, A; Paggi, A; Pistoli, E; Sabbatini, D,
)
1.81
" Adverse effects were rated before treatment onset, at day 3, then every week and at discharge or at discontinuation."( Efficiency and safety of oxcarbazepine in mood disorders: a naturalistic study exploring the interest of plasma dosages.
Droulout, T; Grolleau, A; Misdrahi, D; Molimard, M; Titier, K; Tournier, M; Verdoux, H, 2008
)
0.65
" Adverse events were systematically recorded throughout the study."( Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study.
Chopra, D; Gupta, NK; Kakkar, AK; Kataria, D; Rehan, HS; Unni, KE, 2009
)
0.63
" A significantly greater number of patients in divalproex group experienced one or more adverse drug events as compared to patients in the oxcarbazepine group (66."( Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study.
Chopra, D; Gupta, NK; Kakkar, AK; Kataria, D; Rehan, HS; Unni, KE, 2009
)
0.83
" Also the overall adverse event profile was found to be superior for oxcarbazepine."( Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study.
Chopra, D; Gupta, NK; Kakkar, AK; Kataria, D; Rehan, HS; Unni, KE, 2009
)
0.86
"To evaluate and to compare the possible toxic effects of oxcarbazepine (OXC) and valproic acid (VPA) on retinal ganglion cells (RGCs) in rat."( Retinal ganglion cell toxicity due to oxcarbazepine and valproic acid treatment in rat.
Aktaş, Z; Cansu, A; Erdoğan, D; Goktas, G; Ozdek, S; Serdaroglu, A; Take, G, 2009
)
0.87
"OXC seems to be toxic to RGCs at 100mg/kg dose when it is been given as a monotherapy or combined with VPA."( Retinal ganglion cell toxicity due to oxcarbazepine and valproic acid treatment in rat.
Aktaş, Z; Cansu, A; Erdoğan, D; Goktas, G; Ozdek, S; Serdaroglu, A; Take, G, 2009
)
0.62
"There were no serious adverse drug reactions reported during this study."( Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
Buggy, Y; Fogg, C; Layton, D; Shakir, SA, 2010
)
0.69
" Adverse effects were observed in 11."( [Efficacy and safety of the monotherapy with trileptal (oxcarbazepine) in children and adolescents].
, 2010
)
0.61
" The low frequency and intensity of adverse effects during the treatment with trileptal was observed: there were 93 adverse effects in 60 patients included in the trial; 3 (3."( [Efficacy and safety of the mono- and combined therapy with oxcarbazepine in adult patients].
Badalian, OL; Burd, SG; Glukhova, LIu, 2010
)
0.6
"Co-administration of phenytoin and oxcarbazepine resulted in toxic levels of phenytoin."( Phenytoin toxicity secondary to an oxcarbazepine-phenytoin 2C19 interaction.
Kane, AJ; Soskin, DP; Stern, TA,
)
0.69
" Adverse effects were observed in 11."( [Efficacy and safety of the monotherapy with trileptal (oxcarbazepine) in children and adolescents].
Belousova, ED; Ermolenko, NA; Guzeva, VI; Mironov, MB; Mukhin, KIu; Petrukhin, AS; Tysiachina, MD, 2010
)
0.61
"Analysis of overall tolerability and neurological adverse effects (AEs) of eslicarbazepine acetate (ESL), lacosamide (LCM) and oxcarbazepine (OXC) from double-blind, placebo-controlled trials."( Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Fadda, V; Giovannelli, F; Maratea, D; Verrotti, A; Zaccara, G, 2013
)
0.79
" Adverse event types reflected the drug's established profile."( Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial.
Baroldi, P; Brittain, ST; French, JA; Johnson, JK, 2014
)
0.67
" Adverse event occurrence and discontinuations due to adverse events suggest improved tolerability vs previously published data with immediate-release OXC."( Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial.
Baroldi, P; Brittain, ST; French, JA; Johnson, JK, 2014
)
0.67
" It is being used more and more widely in clinical practice, but its adverse effects should not be ignored."( [Adverse effects of oxcarbazepine].
Fang, S; Gong, ZC, 2015
)
0.74
" This systematic review aimed to assess the prevalence of their adverse effects (AEs) and to provide recommendations on their clinical management."( Management of adverse effects of mood stabilizers.
Hidalgo, D; León-Caballero, J; Murru, A; Pacchiarotti, I; Popovic, D; Vieta, E, 2015
)
0.42
" Treatment-emergent adverse events occurred in 82% (CBZ/OXC), 76% (LTG), 73% (LEV), and 67% (VPA) of patients; most were of mild-to-moderate intensity."( Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.
Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015
)
0.42
" The aim of this study was to examine the frequency of the adverse events of antiepileptic drugs (AEDs), in particular carbamazepine (CBZ) and oxcarbazepine (OXC) in patients with neuralgiform pain using the psychometrically tested Liverpool Adverse Events Profile (AEP) and provide clinicians with guidance as to when to change management."( Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP).
Besi, E; Boniface, DR; Cregg, R; Zakrzewska, JM, 2015
)
0.87
" At each consultation they completed the AEP questionnaire which provides scores of 19-76 with toxic levels being considered as scores >45."( Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP).
Besi, E; Boniface, DR; Cregg, R; Zakrzewska, JM, 2015
)
0.67
" Potential toxic dose for females is approximately 1200 mg of OXC and 800 mg of CBZ and1800mg of OXC and 1200 mg of CBZ for males."( Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP).
Besi, E; Boniface, DR; Cregg, R; Zakrzewska, JM, 2015
)
0.67
" Potentially, females need to be prescribed lower dosages in view of their tendency to reach toxic levels at lower dosages."( Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP).
Besi, E; Boniface, DR; Cregg, R; Zakrzewska, JM, 2015
)
0.67
"To evaluate the relationship between serum concentrations of mono-hydroxy-carbazepine (MHD), the main metabolite of oxcarbazepine (OXC), and the occurrence of adverse effects (AE) in a large group of patients on OXC monotherapy."( Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
May, TW; Sattler, A; Schaefer, M, 2015
)
0.84
" Side effects like genotoxic effects of AEDs are of prime importance resulting from toxic metabolites, free radicals and reactive oxygen species (ROS)."( The genotoxic effect of oxcarbazepine on mice blood lymphocytes.
Akbar, H; Begum, I; Khan, A; Khisroon, M; Mohammadzai, I, 2018
)
0.79
" This study compared adverse event (AE) reporting rates for brand vs."( Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Alatawi, Y; Berg, RL; Cheng, N; Hansen, RA; Page, D; Peissig, PL; Plotkina, AV; Qian, J; Rahman, MM, 2017
)
0.46
" Food and Drug Administration Adverse Event Reporting System between January 2004 to March 2015 with lamotrigine, carbamazepine, and oxcarbazepine listed as primary or secondary suspect were classified as brand, generic, or AG based on the manufacturer."( Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Alatawi, Y; Berg, RL; Cheng, N; Hansen, RA; Page, D; Peissig, PL; Plotkina, AV; Qian, J; Rahman, MM, 2017
)
0.66
"Valproate alone or combined with another AED is associated with the greatest odds of adverse neurodevelopmental outcomes compared with control."( Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis.
Cogo, E; D'Souza, J; Finkelstein, Y; Hemmelgarn, BR; Hutton, B; Kealey, R; MacDonald, H; Reynen, E; Rios, P; Soobiah, C; Straus, SE; Thavorn, K; Tricco, AC; Veroniki, AA; Yazdi, F, 2017
)
0.46
" It still remains unclear how much these drugs are safe during pregnancy."( The neurotoxic effects of prenatal gabapentin and oxcarbazepine exposure on newborn rats.
Ayas, B; Ercument Beyhun, N; Erisgin, Z; Nyengaard, JR; Terzi, Y, 2019
)
0.77
" The aim of this observational cross-sectional study was to compare the A-B Neuropsychological Assessment Schedule (ABNAS), which measures cognitive side effects to the Adverse Events Profile (AEP), which looks at a broader range of side effects, and to investigate drug/dosage relationships with questionnaire scores to help determine a point at which a drug change would be indicated."( Adverse effects of anti-epileptics in trigeminal neuralgiform pain.
Cregg, R; Lee, G; O'Keeffe, AG; Reading, J; Tentolouris-Piperas, V; Zakrzewska, JM, 2018
)
0.48
" Toxic range on the ABNAS was estimated to occur when scores were >43/72 (95% CI: 37."( Adverse effects of anti-epileptics in trigeminal neuralgiform pain.
Cregg, R; Lee, G; O'Keeffe, AG; Reading, J; Tentolouris-Piperas, V; Zakrzewska, JM, 2018
)
0.48
"There is limited literature on cognitive, behaviour and sleep-related adverse effects of levetiracetam and oxcarbazepine among adult epilepsy patients, except for what is available from the initial efficacy trials."( Cognitive, behavioural and sleep-related adverse effects on introduction of levetiracetam versus oxcarbazepine for epilepsy.
Gupta, A; Pandit, AK; Prasad, K; Rajan, R; Shukla, G; Singh, MB; Srivastava, A; Thelengana, A; Vibha, D, 2019
)
0.94
" Trail making test A & B, digit symbol substitution test, Stroop colour and word test, controlled oral word association test and PGI memory scale, Neuropsychiatric Inventory, sleep log and ESS-I were used for assessment of cognitive, behaviour and sleep-related adverse effects."( Cognitive, behavioural and sleep-related adverse effects on introduction of levetiracetam versus oxcarbazepine for epilepsy.
Gupta, A; Pandit, AK; Prasad, K; Rajan, R; Shukla, G; Singh, MB; Srivastava, A; Thelengana, A; Vibha, D, 2019
)
0.73
"On cross-sectional as well as on longitudinal assessment, nearly one-fifth of patients on levetiracetam have behaviour related adverse effects, with dose modification required for half among these."( Cognitive, behavioural and sleep-related adverse effects on introduction of levetiracetam versus oxcarbazepine for epilepsy.
Gupta, A; Pandit, AK; Prasad, K; Rajan, R; Shukla, G; Singh, MB; Srivastava, A; Thelengana, A; Vibha, D, 2019
)
0.73
" Safety and tolerability were assessed throughout follow-up by evaluating adverse events (AEs) and ESL discontinuation due to AEs, respectively."( Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice.
Assenza, G; McMurray, R; Peltola, J; Rocamora, R; Villanueva, V, 2020
)
0.77
" LEV has milder adverse events than OXC and LTG in clinical practice."( Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: An observational study in the real world.
Li, R; Li, Y; Ou, S; Pan, S; Wang, Y; Xia, L; Zhou, Q, 2020
)
0.8
"This study aimed to develop a pharmacokinetic (PK) model of oxcarbazepine (OXC) and analyse the relationship between monohydroxylated derivative (MHD), an active metabolite of OXC, and the adverse events of OXC."( Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy.
Chu, K; Jang, IJ; Jang, Y; Kim, TJ; Lee, S; Lee, SK; Yoon, S; Yu, KS, 2021
)
1.09
"Stevens-Johnson syndrome and toxic epidermal necrolysis are viewed as the most severe drug-induced types of cutaneous adverse reactions, with high rates of morbidity and mortality."( Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system.
Fang, W; Pan, L; Sun, Q; Xu, C; Zhang, J; Zhang, Y, 2021
)
0.92
" Pharmacovigilance tools were employed for the quantitative detection of signals, where a signal represents a drug-associated adverse event, including the reporting odds ratio, proportional reporting ratio, an information component given by a Bayesian confidence propagation neural network, and the empirical Bayes geometric mean."( Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system.
Fang, W; Pan, L; Sun, Q; Xu, C; Zhang, J; Zhang, Y, 2021
)
0.92
"The total number of reports identified as Stevens-Johnson syndrome or toxic epidermal necrolysis associated with carbamazepine or oxcarbazepine included in this study was 1231."( Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system.
Fang, W; Pan, L; Sun, Q; Xu, C; Zhang, J; Zhang, Y, 2021
)
1.12
"The results of our study are consistent with clinical observations, suggesting the necessity for further clinical research on Stevens-Johnson syndrome and toxic epidermal necrolysis associated with carbamazepine or oxcarbazepine."( Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system.
Fang, W; Pan, L; Sun, Q; Xu, C; Zhang, J; Zhang, Y, 2021
)
1.1
" Adverse events were also recorded."( Effectiveness and safety of perampanel in Chinese paediatric patients (2-14 years) with refractory epilepsy: a retrospective, observational study.
Chen, X; Dai, Y; Li, R; Liu, M; Qu, R; Zhu, Y, 2021
)
0.62
"This study aimed to evaluate the association between eye disorders and several newer AEDs, and also to examine the differences in the frequency of adverse events across individual AEDs through data mining of the self-reporting US Food and Drug Administration Adverse Event Report System (FAERS) database."( Eye disorders associated with newer antiepileptic drugs: A real-world disproportionality analysis of FDA adverse event reporting system.
Chen, L; Hu, W; Li, H; Liu, J, 2022
)
0.72
" Although oxcarbazepine (OXC) is often considered efficacious for focal seizures in NCC, due to adverse effects, newer ASMs like levetiracetam (LCM) and lacosamide are also being explored."( Comparative Efficacy and Safety of Lacosamide and Oxcarbazepine for Seizure Control in Children with Newly Diagnosed Solitary Neurocysticercosis.
Kumar, V; Panda, PK; Sharawat, IK; Sherwani, P, 2022
)
1.38
" Seizure control, electroencephalographic abnormalities, resolution of inflammatory granulomas and adverse effects were compared between two arms at 12 and 24 weeks."( Comparative Efficacy and Safety of Lacosamide and Oxcarbazepine for Seizure Control in Children with Newly Diagnosed Solitary Neurocysticercosis.
Kumar, V; Panda, PK; Sharawat, IK; Sherwani, P, 2022
)
0.97
" Patients receiving OXC had more frequent treatment-emergent adverse events (p = 0."( Comparative Efficacy and Safety of Lacosamide and Oxcarbazepine for Seizure Control in Children with Newly Diagnosed Solitary Neurocysticercosis.
Kumar, V; Panda, PK; Sharawat, IK; Sherwani, P, 2022
)
0.97
"Lacosamide appears to be efficacious and safe for achieving seizure freedom in patients with solitary viable parenchymal neurocysticercosis."( Comparative Efficacy and Safety of Lacosamide and Oxcarbazepine for Seizure Control in Children with Newly Diagnosed Solitary Neurocysticercosis.
Kumar, V; Panda, PK; Sharawat, IK; Sherwani, P, 2022
)
0.97

Pharmacokinetics

This study aimed to develop a pharmacokinetic (PK) model of oxcarbazepine (OXC) and analyse the relationship between monohydroxylated derivative (MHD), an active metabolite of OXC, and the adverse events. d(-1) given twice daily had 1 to 4 blood samples collected per patient.

ExcerptReferenceRelevance
" The pharmacokinetic study was repeated under steady-state conditions after 3 months of drug intake in 6 of these subjects."( First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite.
Dickinson, RG; Dunstan, PR; Eadie, MJ; Hooper, WD, 1989
)
0.53
" The time-concentration curves showed a median Tmax of 8 h followed by a plateau until 24 h indicating saturable kinetic processes."( Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations.
Jönsson, B; Klitgaard, NA; Kristensen, O; Sindrup, S, 1983
)
0.49
" Pharmacokinetic parameters of monohydroxyoxcarbazepine and dihydroxyoxcarbazepine were determined from plasma and urine samples obtained on the tenth day of each treatment period."( Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine.
Banfield, CR; Colucci, RD; Hulsman, JA; Lin, CC; Meehan, JW; Mojaverian, P; Nezamis, J; Radwanski, E; Reidenberg, P; Rentmeester, TW, 1995
)
0.78
" The apparent elimination half-life of the monohydroxy-metabolite [19 (SD 3) h] in these patients was about twice that in healthy subjects."( The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites.
Aldigier, JC; Darragon, T; Godbillon, J; Hillion, D; Jungers, P; Kourilsky, O; Lecaillon, JB; Menard, F; Meyer, P; Rouan, MC, 1994
)
0.53
" Steady-state pharmacokinetic parameters of FEL and its pyridine metabolite were not influenced by the single dose of OXC."( Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine.
Bendoni, L; Gangemi, PF; Menge, GP; Monza, GC; Schwabe, S; Zaccara, G, 1993
)
0.55
" Three of the new drugs, gabapentin, topiramate and vigabatrin, are more promising on the basis of their pharmacokinetic features."( Comparative pharmacokinetics of the newer antiepileptic drugs.
Bialer, M, 1993
)
0.29
" The terminal elimination half-life (t1/2z) is relatively long in neonates; it then decreases during the first postnatal month to lower values than in adults, and then progressively increases with age due to an age-dependent decrease in the metabolic rate."( Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.
Avanzini, G; Battino, D; Estienne, M, 1995
)
0.49
" All the drugs can be conveniently given as a twice daily dosage apart from gabapentin, which has a short half-life and a midday dose is needed."( Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine.
Binnie, CD; Elwes, RD, 1996
)
0.51
"This article surveys the pharmacokinetic parameters for the new antiepileptic drugs (AEDs): felbamate, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, and vigabatrin."( Pharmacokinetics of new antiepileptic drugs.
Gram, L, 1996
)
0.5
" No significant changes were observed in the mean values of OXC pharmacokinetic parameters (Cmax, Tmax, t1/2 and AUC0-infinity) between the control and the pre-treated groups."( Effect of valproic acid on the pharmacokinetic profile of oxcarbazepine in the rat.
al-Hassan, MI; Bawazir, SA; Matar, KM; Nicholls, PJ; Tekle, A, 1999
)
0.55
" Because 10-hydroxycarbazepine is a chiral molecule, the objective of the study was to perform a stereoselective pharmacokinetic analysis of 10-hydroxycarbazepine in humans."( Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects.
Bialer, M; Perucca, E; Sintov, A; Volosov, A; Xiaodong, S; Yagen, B, 1999
)
0.53
" The difference in the pharmacokinetic parameters found after administration of individual MHD enantiomers compared with the administration of MHD in a racemic form suggests the possibility of interaction between the two enantiomers."( Comparative stereoselective pharmacokinetic analysis of 10-hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs.
Bialer, M; Volosov, A; Yagen, B, 2000
)
0.31
" The half-life of MHD was 10."( [Pharmacokinetic variability of oxcarbazepine in epileptic patients].
Bercellini, MA; Rubio, MC; Saidón, P; Viola, MS, 2000
)
0.59
" d(-1) given twice daily had 1 to 4 blood samples collected per patient for population pharmacokinetic analysis of oxcarbazepine's major bioactive 10-monohydroxy metabolite."( Pharmacokinetic drug interactions in children taking oxcarbazepine.
D'souza, J; Hossain, M; Milosavljev, S; Sallas, WM, 2003
)
0.78
"The population pharmacokinetic data for 10-monohydroxy metabolite consisted of a total of 376 observations from 109 patients, aged 3 to 17 years."( Pharmacokinetic drug interactions in children taking oxcarbazepine.
D'souza, J; Hossain, M; Milosavljev, S; Sallas, WM, 2003
)
0.57
"The pharmacokinetic properties of a drug are the primary deter-minant of the extent and duration of drug action, and influence susceptibility to clinically important drug interactions."( The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
Johannessen, SI; Perucca, E, 2003
)
0.32
"75-4h and 6h postdose, after which they declined with an approximate mean apparent terminal half-life of 8-17h and 7-12h, respectively."( Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans.
Almeida, L; Soares-da-Silva, P, 2003
)
0.32
" Median maximum plasma concentrations of the major metabolite (licarbazepine, (+/-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide) were attained (t(max)) at 2 to 3 h postdose; thereafter, plasma concentrations declined with a mean apparent terminal half-life of 9 to 13 h following repeated dosing."( Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.
Almeida, L; Soares-da-Silva, P, 2004
)
0.32
" Part I was a pharmacokinetic study in children stratified by age (2-5 years and 6-12 years) and randomized to receive a single oxcarbazepine dose of 5 mg/kg or 15 mg/kg."( Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy.
Bulteau, C; D'Souza, J; Dulac, O; Markabi, S; Motte, J; Pons, G; Rey, E; Sturm, Y; Tran, A, 2004
)
1.97
" However, these combinations were associated with significant pharmacokinetic interactions, in that LCZ increased brain TPM (94%), OXC (21%), FBM (46%), and LTG (8%) concentrations."( Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model.
Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2005
)
0.54
" However, these conclusions are confounded by the fact that LCZ is associated with significant pharmacokinetic interactions."( Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model.
Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2005
)
0.54
" Simultaneously, the effects on hippocampal monoamines were studied as pharmacodynamic markers for the anticonvulsant activity."( Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity.
Clinckers, R; Ebinger, G; Meurs, A; Michotte, Y; Smolders, I, 2005
)
0.54
" Pharmacokinetic parameters were determined by noncompartmental methods."( Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.
Ascher, J; Bullman, J; Job, S; Palmer, J; Sidhu, J; Theis, JG, 2005
)
0.59
" The effects on dopamine and serotonin levels are therefore proposed as pharmacodynamic markers for the anticonvulsant activity of these compounds."( Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine.
Clinckers, R; Ebinger, G; Meurs, A; Michotte, Y; Smolders, I, 2005
)
0.54
" Brain AED concentrations were determined to ascertain any pharmacokinetic contribution to the observed antiseizure effect."( Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis.
Andres, MM; Cioczek-Czuczwar, A; Czuczwar, P; Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2006
)
0.33
"These preclinical data would suggest that LEV in combination with TPM is associated with beneficial anticonvulsant pharmacodynamic interactions."( Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis.
Andres, MM; Cioczek-Czuczwar, A; Czuczwar, P; Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2006
)
0.33
" For drugs that are eliminated renally completely unchanged (gabapentin, pregabalin and vigabatrin) or mainly unchanged (levetiracetam and topiramate), the pharmacokinetic variability is less pronounced and more predictable."( Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Johannessen, SI; Tomson, T, 2006
)
0.33
" Quinidine Cmax decreased by means of 29% (CI: 16-40, p=0."( A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4.
Andreasen, AH; Brøsen, K; Damkier, P, 2007
)
0.56
"Blood samples for the pharmacokinetic assessment were taken at pre-dose, and 1, 2, 3, 4, 6, 8, 12 and 24h post-dose at steady-state in 51 patients stabilised on chronic (beyond 1 year) treatment with ESL 400mg (n=7), 800mg (n=26) or 1200mg (n=18) once-daily."( Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.
Almeida, L; Elger, C; Falcão, A; Halász, P; Perucca, E; Soares-da-Silva, P, 2011
)
0.37
" The major compound in plasma was the active metabolite eslicarbazepine, which reached maximum concentrations (C(max)) 2h post-dose; thereafter, its plasma concentrations declined with a mean apparent half-life of 13, 14, and 20h in patients receiving ESL doses of 400, 800, and 1200mg once daily, respectively."( Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.
Almeida, L; Elger, C; Falcão, A; Halász, P; Perucca, E; Soares-da-Silva, P, 2011
)
0.37
" A population pharmacokinetic model was developed using NONMEM."( Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy.
Hong, SB; Huh, W; Joo, EY; Kim, JR; Kim, SR; Ko, JW; Lee, SY; Park, KJ; Seo, DW,
)
0.39
" In population pharmacokinetic modeling, the apparent clearance of OHC was higher by 31."( Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy.
Hong, SB; Huh, W; Joo, EY; Kim, JR; Kim, SR; Ko, JW; Lee, SY; Park, KJ; Seo, DW,
)
0.39
" Population pharmacokinetic analysis showed that the apparent clearance of OHC increased with comedication with EIAEDs."( Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy.
Hong, SB; Huh, W; Joo, EY; Kim, JR; Kim, SR; Ko, JW; Lee, SY; Park, KJ; Seo, DW,
)
0.39
" There is still insufficient documentation regarding pharmacokinetic variability of these AEDs in different patient groups."( Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
Baftiu, A; Johannessen Landmark, C; Johannessen, SI; Larsson, PG; Rytter, E; Tysse, I; Valsø, B, 2012
)
0.6
"The purpose of this study was to compare age and comedication as factors contributing to pharmacokinetic variability between 4 newer AEDs (lamotrigine, levetiracetam, oxcarbazepine, and topiramate) among patients with refractory epilepsy."( Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
Baftiu, A; Johannessen Landmark, C; Johannessen, SI; Larsson, PG; Rytter, E; Tysse, I; Valsø, B, 2012
)
0.79
" The interindividual pharmacokinetic variability was extensive, as illustrated by a 10-fold variability in serum concentration compared with dose."( Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
Baftiu, A; Johannessen Landmark, C; Johannessen, SI; Larsson, PG; Rytter, E; Tysse, I; Valsø, B, 2012
)
0.6
"Age and comedication are important contributors to pharmacokinetic variability."( Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
Baftiu, A; Johannessen Landmark, C; Johannessen, SI; Larsson, PG; Rytter, E; Tysse, I; Valsø, B, 2012
)
0.6
"This study was to establish the population pharmacokinetic (PPK) model of pharmacologically active metabolite of oxcarbazepine (OXC) and to estimate PPK parameters for the optimal individuation administration of OXC in Chinese children with epilepsy."( Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Liu, ZS; Peng, J; Wang, Y; Xu, H; Zhang, HN, 2014
)
0.9
" Pharmacokinetic parameters were estimated according to a one-compartment model with first-order absorption and elimination."( Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Liu, ZS; Peng, J; Wang, Y; Xu, H; Zhang, HN, 2014
)
0.69
"The purpose of this study is to investigate the effects of multiple-trough sampling design and nonlinear mixed effect modeling (NONMEM) algorithm on the estimation of population and individual pharmacokinetic parameters."( [Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters].
Ding, JJ; Jiao, Z; Ling, J; Qian, LX, 2014
)
0.4
"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0."( Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy.
Chen, YJ; Gao, P; Liu, MC; Niu, CH; Peng, J; Wang, Y; Xu, H; Zhang, HN, 2014
)
0.67
"The aim of the study was to develop a population pharmacokinetic (PPK) model of oxcarbazepine and optimize the treatment of oxcarbazepine in Chinese patients with epilepsy."( Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
Hao, G; Lv, C; Xu, W; Yu, Y; Zhang, Q, 2016
)
0.93
" As a third-generation medication, ESL is believed to have favorable efficacy/safety profile and pharmacokinetic properties in comparison with related drugs (carbamazepine and oxcarbazepine)."( Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.
Banach, M; Borowicz, KK; Czuczwar, SJ, 2015
)
0.61
"The aim of the paper was to evaluate pharmacodynamic and pharmacokinetic properties of ESL with aspect to epilepsy treatment."( Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.
Banach, M; Borowicz, KK; Czuczwar, SJ, 2015
)
0.42
" The pharmacokinetic (PK) profiles of MHD were evaluated in pediatric epileptic patients and a possible ethnic difference in PK of MHD between Japanese and non-Japanese pediatric patients was assessed."( Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
Bouillon, T; Fink, M; Hirota, T; Sugiyama, I; Suzuki, H; Yamaguchi, M, 2015
)
0.65
" This method is suitable for pharmacokinetic study in small animals."( Evaluation of the Effects of Ketoconazole and Voriconazole on the Pharmacokinetics of Oxcarbazepine and Its Main Metabolite MHD in Rats by UPLC-MS-MS.
Cai, JP; Chen, M; Chen, X; Gu, E; Hu, G; Wang, L; Wang, S; Zheng, X; Zhou, H, 2016
)
0.66
" Noncompartmental pharmacokinetic analysis was performed using the WinNonlin program."( Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.
Alexandre Junior, V; Antunes, Nde J; Coelho, EB; Della Pasqua, O; Lanchote, VL; Marques, MP; Takayanagui, OM; Tozatto, E; Wichert-Ana, L, 2016
)
0.69
" The purpose of the study was to investigate 2-way pharmacokinetic interactions between ESL and other AEDs as compared to OXC and CBZ."( The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice.
Baftiu, A; Brodtkorb, E; Burns, ML; Dinarevic, J; Johannessen Landmark, C; Johannessen, SI; Kufaas, RF; Reimers, A; Svendsen, T, 2016
)
0.66
"Possible pharmacokinetic interactions have been studied for ESL as compared to OXC and CBZ."( The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice.
Baftiu, A; Brodtkorb, E; Burns, ML; Dinarevic, J; Johannessen Landmark, C; Johannessen, SI; Kufaas, RF; Reimers, A; Svendsen, T, 2016
)
0.66
"This population pharmacokinetic model of oxcarbazepine supports current dose recommendations, except for 10-kg children with concomitant EIAEDs and 50-kg children without EIAEDs."( Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
Chiron, C; Comets, E; Dulac, O; Jullien, V; Pons, G; Rey, E; Rodrigues, C, 2017
)
1.01
" Therefore, this study aimed to establish a population pharmacokinetic (PPK) model of LTG in Chinese children with epilepsy and to comprehensively evaluate the effects of genetic variations in drug-metabolizing enzymes, transporters, and a transcriptional regulator on LTG pharmacokinetics."( A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy.
Chen, Y; Lu, T; Wang, H; Wang, Z; Xu, S; Zhao, L; Zhao, M, 2018
)
0.48
" There are no MHD population pharmacokinetic (PPK) models that describe the influence of genetic factors on MHD pharmacokinetics (PK)."( Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
Jiao, Z; Li, XW; Lin, WW; Lin, XH; Rao, X; Wang, CL; Zeng, DY; Zhang, J, 2019
)
0.8
" This study established a population pharmacokinetic (PPK) model of MHD in Chinese children with epilepsy and conducted a dosage simulation in order to provide support for individualized OXC treatment."( Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy.
Chen, CY; Cui, YM; Wu, Y; Yang, T; Zhao, X; Zhou, Y, 2019
)
0.77
" Serum and brain levels of antiepileptic drugs and cannabidiol were determined by using HPLC in order to ascertain any pharmacokinetic contribution to the observed behavioral effects."( Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies.
Nieoczym, D; Socała, K; Szafarz, M; Wlaź, P; Wyska, E, 2019
)
0.51
"This study aimed to develop a pharmacokinetic (PK) model of oxcarbazepine (OXC) and analyse the relationship between monohydroxylated derivative (MHD), an active metabolite of OXC, and the adverse events of OXC."( Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy.
Chu, K; Jang, IJ; Jang, Y; Kim, TJ; Lee, S; Lee, SK; Yoon, S; Yu, KS, 2021
)
1.09
" Owing to the high pharmacokinetic variability, several population pharmacokinetic models have been developed for oxcarbazepine to explore potential covariates that affect its pharmacokinetic variation."( Population pharmacokinetics of oxcarbazepine: a systematic review.
Chen, YT; Jiao, Z; Li, ZR; Lin, WW; Wang, CY; Yin, YW; Zhu, M, 2021
)
1.12
"This review summarizes the published population pharmacokinetic studies of oxcarbazepine in children and adults available in PubMed and Embase databases."( Population pharmacokinetics of oxcarbazepine: a systematic review.
Chen, YT; Jiao, Z; Li, ZR; Lin, WW; Wang, CY; Yin, YW; Zhu, M, 2021
)
1.14
" To address this knowledge gap, physiologically-based pharmacokinetic (PBPK) modeling was performed in the PK-Sim software using literature data from children greater than or equal to 2 years of age."( Physiologically-based pharmacokinetic modeling of oxcarbazepine and levetiracetam during adjunctive antiepileptic therapy in children and adolescents.
Gonzalez, D; Karatza, E; Sinha, J, 2022
)
0.97
" Using this fact we aimed to develop an MHD population pharmacokinetic (PPK) model in Chinese adult epileptic patients to facilitate the clinical implementation of model-guided individualised drug therapy."( Population pharmacokinetics of oxcarbazepine 10-monohydroxy derivative in Chinese adult epileptic patients.
Dai, H; Hu, Y; Li, X; Yang, Q; Zhang, X, 2023
)
1.2

Compound-Compound Interactions

Oxcarbazepine increased the apparent clearance of 10-monohydroxy metabolite by 31% to 35%. Carbamazepine levels decreased by 15% and phenobarbital levels increased by 14%.

ExcerptReferenceRelevance
"Our objective was to evaluate the drug-drug interactions of oxcarbazepine with coadministered antiepileptic drugs in children."( Pharmacokinetic drug interactions in children taking oxcarbazepine.
D'souza, J; Hossain, M; Milosavljev, S; Sallas, WM, 2003
)
0.81
" Carbamazepine, phenobarbital, or phenytoin administered with oxcarbazepine increased the apparent clearance of 10-monohydroxy metabolite by 31% to 35%, whereas carbamazepine levels decreased by 15% and phenobarbital levels increased by 14%."( Pharmacokinetic drug interactions in children taking oxcarbazepine.
D'souza, J; Hossain, M; Milosavljev, S; Sallas, WM, 2003
)
0.81
" The cases were categorized into OXC monotherapy (n = 78), OXC in combination with EIAED (n = 73), and OXC in combination with non-EIAED (n = 103)."( Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy.
Hong, SB; Huh, W; Joo, EY; Kim, JR; Kim, SR; Ko, JW; Lee, SY; Park, KJ; Seo, DW,
)
0.39
" Hence, potential drug-drug interactions (DDIs) may occur between these 2 drugs and antiretrovirals."( Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
Atzori, C; Baldelli, S; Cattaneo, D; Cozzi, V; Filice, C; Fusi, M; Gervasoni, C; Micheli, V, 2020
)
0.8

Bioavailability

Oxcarbazepine (trileptal) oral suspension has been reformulated and a study was performed to compare the bioavailability after single doses and at steady state. Co-administration of verapamil resulted in a modest increase of the apparent bioavailability by 12% (10-28)

ExcerptReferenceRelevance
" The results indicate that OCBZ, like most antiepileptic drugs (AEDs), decreases the bioavailability of EE and LNG, perhaps by affecting metabolism or protein binding."( Possible interaction between oxcarbazepine and an oral contraceptive.
Haring, P; Klosterskov Jensen, P; Menge, GP; Saano, V; Svenstrup, B,
)
0.42
" This reduction in FEL bioavailability is much smaller than that observed after co-administration of carbamazepine (CBZ) (i."( Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine.
Bendoni, L; Gangemi, PF; Menge, GP; Monza, GC; Schwabe, S; Zaccara, G, 1993
)
0.55
" OXC has a high bioavailability and is 40% protein-bound."( [Oxcarbazepine].
Arroyo, S, 2001
)
1.22
" The goal of the study was to compare the bioavailability after single doses and at steady state of the FMI versus CMF and CTF as well."( Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects.
D'Souza, J; Flesch, G; Hossain, M; Souppart, C; Tudor, D, 2002
)
1.76
"Oxcarbazepine (trileptal) oral suspension has been reformulated and a study was performed to compare the bioavailability after single doses and at steady state of the current and former oral suspension versus the marketed film-coated tablets and to compare the bioavailability of the current and former oral suspension."( Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects.
Bonner, J; Camisasca, R; Denouel, J; Flesch, G; Tudor, D, 2003
)
2.03
" The bioavailability of the oral formulation of oxcarbazepine is high (>95%)."( Clinical pharmacokinetics of oxcarbazepine.
Korn-Merker, E; May, TW; Rambeck, B, 2003
)
0.87
" Relative bioavailability was calculated and the C(max) and AUCs were compared using Wilcoxon signed-rank tests."( Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension.
Clemens, PL; Cloyd, JC; Kriel, RL; Remmel, RP, 2007
)
0.57
"Monohydroxy derivative bioavailability following rectal administration of oxcarbazepine suspension is significantly lower than following oral administration, most likely because of poor oxcarbazepine water solubility."( Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension.
Clemens, PL; Cloyd, JC; Kriel, RL; Remmel, RP, 2007
)
0.8
" This study was performed to characterize the disposition of the two enantiomers of MHD after oral and intravenous administration and to estimate the bioavailability of MHD after a single oral dose administration of OXC compared to a single intravenous administration of MHD."( Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
Czendlik, C; Flesch, G; Lloyd, P; Renard, D, 2011
)
0.62
" Age was a significant factor contributing to pharmacokinetic variability in individuals using LTG, OXC, and CBZ with increasing clearance as a function of bioavailability (Cl/F) over age 18, a maximum Cl/F at 33years (CBZ) and 36 years (LTG and OXC), and a gradual decrease of Cl/F towards older age."( The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study.
Lindhout, D; Sander, JW; Wegner, I; Wilhelm, AJ, 2013
)
0.66
" Due to their surface active properties, PC forms bilayers at the aqueous interface, thereby enabling encapsulated drug to benefit from better bioavailability and stability."( Identifying lipidic emulsomes for improved oxcarbazepine brain targeting: In vitro and rat in vivo studies.
Awad, GA; El-Zaafarany, GM; Mansour, S; Soliman, ME, 2016
)
0.7
" Co-administration of verapamil resulted in a modest increase of the apparent bioavailability of oxcarbazepine by 12% (10-28), but did not affect parent or metabolite clearances."( Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
Alexandre Junior, V; Antunes, NJ; Coelho, EB; Della Pasqua, O; Lanchote, VL; Takayanagui, OM; Tozatto, E; van Dijkman, SC; van Hasselt, JGC; Wichert-Ana, L, 2017
)
0.96
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Poor bioavailability is a major obstacle in the development of an effective dosage form of the poorly soluble drugs."( Improved bioavailability of oxcarbazepine, a BCS class II drug by centrifugal melt spinning: In-vitro and in-vivo implications.
Abbas, N; Arshad, MS; Bukhari, NI; Hussain, A; Hussain, F; Nasir, S, 2021
)
0.92

Dosage Studied

The goal of the study was to evaluate the safety and efficacy of a broad oxcarbazepine (OXC) dosage range (600, 1200, and 2400 mg/d) as adjunctive therapy for uncontrolled partial seizures. A significant decrease of ratio plasma concentration of 10-monohydroxy derivate (MHD) of oxcarbzepine to dosage was found by 26.

ExcerptRelevanceReference
" On the basis of these considerations and clinical reports describing the use of these drugs, we make dosage recommendations to enable the practitioner to individualize therapeutic regimens."( Drugs used in the management of trigeminal neuralgia.
Patsalos, PN; Zakrzewska, JM, 1992
)
0.28
" After reaching steady-state conditions by repeated administration of warfarin, the prothrombin time (Quick value) was assessed before and after single (600 mg) and multiple dosing (450 mg twice daily in 1 week) of OCBZ."( Oxcarbazepine does not affect the anticoagulant activity of warfarin.
Klosterskov Jensen, P; Krämer, G; Menge, GP; Stoll, KD; Tettenborn, B,
)
1.57
" In particular, the TTV values were virtually unaffected by OXC administration, while the effects of CBZ on both variables were particularly evident at 8 and 10 h after dosing which correspond to the time at which the plasma concentrations of CBZ and of its 10,11-epoxide reach the peak."( Effects of oxcarbazepine and carbamazepine on the central nervous system: computerised analysis of saccadic and smooth-pursuit eye movements.
Gangemi, PF; Massi, S; Messori, A; Monza, GC; Parigi, A; Valenza, T; Zaccara, G, 1992
)
0.67
" for 10 days) on the steady-state plasma concentrations of Oxcarbazepine (OXC), its active metabolite 10, 11-dihydro-10-hydroxy-carbazepine (MHD) and the corresponding diol (DHD) were studied in a randomized, double-blind cross-over placebo-controlled trial in 6 epileptic patients stabilized on a fixed dosage of OXC."( Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy.
Artesi, C; Di Perri, R; Fazio, A; Oteri, G; Perucca, E; Pisani, F; Xiao, B, 1994
)
0.79
"min-1), the glucuronides of oxcarbazepine and its monohydroxy-metabolite are likely to accumulate during repeated administration, and dosage adjustment of oxcarbazepine in these patients could not be proposed from this single administration study."( The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites.
Aldigier, JC; Darragon, T; Godbillon, J; Hillion, D; Jungers, P; Kourilsky, O; Lecaillon, JB; Menard, F; Meyer, P; Rouan, MC, 1994
)
0.83
" The usually administered dosage of OCBZ is approximately 50% higher than that of CBZ."( Oxcarbazepine: clinical development program.
Schwabe, S, 1994
)
1.73
" Median AUCs of CBZ, VPA and PHT during a dosage interval did not differ significantly after treatment with OXC and placebo."( A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.
Blacklaw, J; Brodie, MJ; Connelly, D; Forrest, G; Gillham, RA; McKee, PJ; Walker, SM, 1994
)
0.53
" In patients, linear and dose-proportional kinetics with no autoinduction of metabolism simplify OCBZ dosage adjustment."( Clinical pharmacology and pharmacokinetics of oxcarbazepine.
Dieterle, W; Flesch, G; Lloyd, P, 1994
)
0.55
" The recommended dosage of OCBZ as monotherapy for adults with epilepsy is 600-1,200 mg orally per day but may be higher in patients with refractory seizures and in patients requiring combination therapy."( Practical aspects of oxcarbazepine treatment.
Dam, M, 1994
)
0.61
" Blood samples for measurement of FEL and its pyridine metabolite (determined by gas-chromatography) were drawn just before dosing and at 2, 4, 6, 8, 10, 12, and 24 h after dosing on days 5, 6, and 13."( Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine.
Bendoni, L; Gangemi, PF; Menge, GP; Monza, GC; Schwabe, S; Zaccara, G, 1993
)
0.55
" All the drugs can be conveniently given as a twice daily dosage apart from gabapentin, which has a short half-life and a midday dose is needed."( Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine.
Binnie, CD; Elwes, RD, 1996
)
0.51
" Phenobarbital cotreatment (45 mg/kg/day) with OXC (1100 mg/kg/day) did not lead to changes in the incidence of malformation when compared with OXC (1100 mg/kg/day) dosed alone."( Teratogenicity of carbamazepine-10, 11-epoxide and oxcarbazepine in the SWV mouse.
Amore, BM; Bennett, GD; Finnell, RH; Kalhorn, TF; Nelson, SD; Skiles, GL; Slattery, JT; Wlodarczyk, B, 1996
)
0.55
" Specific indications and dosage schedules have been provided."( New antiepileptic drugs.
Brodie, MJ; Wilson, EA, 1996
)
0.29
" Because dosing is often modest, cost should rarely be the overriding factor in choosing a drug for a patient with newly diagnosed epilepsy in the developed world."( Monostars: an aid to choosing an antiepileptic drug as monotherapy.
Brodie, MJ, 1999
)
0.3
"The goal of the study was to evaluate the safety and efficacy of a broad oxcarbazepine (OXC) dosage range (600, 1200, and 2400 mg/d) as adjunctive therapy for uncontrolled partial seizures and to determine the relationship between trough plasma 10-monohydroxy derivative concentrations and OXC safety and efficacy."( Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy.
Barcs, G; D'Souza, J; Elger, CE; Flesch, G; Kramer, L; Moore, A; Scaramelli, A; Stefan, H; Sturm, Y; Walker, EB, 2000
)
1.98
" The authors conclude that it is unnecessary to adjust the oxcarbazepine dosage when performing single-volume plasma exchanges or even multiple exchanges during an extended period."( Removal of 10-hydroxycarbazepine by plasmapheresis.
Balslev, T; Christensen, J; Dam, M; Heinsvig, EM; Poulsen, JH; Villadsen, J, 2001
)
0.55
" Dosage can be increased by 8-10 mg/kg/day in weekly increments if necessary for seizure control."( Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view.
Arroyo, S; Baulac, M; Dam, M; Dulac, O; Friis, ML; Kälviäinen, R; Krämer, G; Pedersen, B; Sachdeo, R; Schmidt, D; van Parys, J, 2001
)
0.58
" Although structurally similar to carbamazepine, significant differences exist in the pharmacokinetics, drug interaction potential, adverse-effect profile, and dosage and titration between these two agents, and they should be considered distinct therapeutic agents."( Oxcarbazepine in the treatment of epilepsy.
Glauser, TA, 2001
)
1.75
" According to the literature, OCBZ is regarded as effective in acute mania and appears to reduce the dosage of neuroleptics required for the treatment of affective and schizoaffective disorders."( Oxcarbazepine in affective and schizoaffective disorders.
Dietrich, DE; Emrich, HM; Kropp, S, 2001
)
1.75
" An exchange in a dosage ratio of 1:1-1:1."( [Ad hoc change from carbamazepine to oxcarbazepine--effectiveness and tolerance. A retrospective analysis].
Homberg, V; Kowalik, A; Schulze-Bonhage, A, 2001
)
0.58
" Patients were first treated with oxcarbazepine 1200 +/- 600 mg daily dosage (mean +/- SD) and subsequently with surgery of their choice."( Long-term cohort study comparing medical (oxcarbazepine) and surgical management of intractable trigeminal neuralgia.
Patsalos, PN; Zakrzewska, JM, 2002
)
0.86
" The aim of this study was to develop and validate a HPLC method allowing simultaneous dosage of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn."( LC determination of oxcarbazepine and its active metabolite in human serum.
Levert, H; Odou, P; Robert, H, 2002
)
0.86
" Dosage of OXC, serum levels of the active metabolite of OXC, antiepileptic comedication or patients' age and gender were of no predictive value for the development of hyponatremia."( Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children.
Boenigk, HE; Holtmann, M; Korn-Merker, E; Krause, M; Opp, J; Tokarzewski, M, 2002
)
1.76
" Additional supporting findings demonstrated that 43-71% of patients with partial onset, generalized or undetermined epilepsy were seizure free after oxcarbazepine monotherapy (mean dosage 27."( Oxcarbazepine: a review of its use in children with epilepsy.
Bang, L; Goa, K, 2003
)
1.96
" Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response."( The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
Johannessen, SI; Perucca, E, 2003
)
0.32
"This study is the open-label extension phase that followed a multicenter, randomized, double-blind, dose-response clinical study of OXC monotherapy in patients with medically refractory partial epilepsy."( Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy.
Beydoun, A; D'Souza, J; Kutluay, E; McCague, K; Sachdeo, RC, 2003
)
0.58
" Additional supporting findings demonstrated that 43-71% of patients with partial onset, generalised or undetermined epilepsy were seizure free after oxcarbazepine monotherapy (mean dosage 27."( Spotlight on oxcarbazepine in epilepsy.
Bang, LM; Goa, KL, 2004
)
0.89
" It is also recommended to avoid saliva collection within 8 hours after OXC dosing to allow complete absorption and transformation of the parent drug."( Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD).
Baumann, RJ; DeGrauw, TJ; Fakhoury, TA; Grim, SA; Miles, MV; Ryan, MA; Strawsburg, RH; Tang, PH, 2004
)
0.61
" Within each of 4 dosage groups of 8 healthy male adult subjects, 2 subjects were randomized to receive placebo, and the remaining 6 subjects were randomized to receive BIA 2-093 (200 mg bid, 400 mg qd, 800 mg qd, and 1200 mg qd) for 8 days."( Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.
Almeida, L; Soares-da-Silva, P, 2004
)
0.32
" Two hours after a documented overdosage of more than 100 tablets oxcarbazepine, the serum level of the parent compound was 10-fold higher than the therapeutic dosage (31."( Severe overdosage with the antiepileptic drug oxcarbazepine.
Cilissen, J; De Heer, F; Janknegt, R; L'Ortije, WH; Nel, JE; van Opstal, JM, 2004
)
0.82
"This article reviews preclinical and clinical data on the efficacy and tolerability of these 4 AEDs in the management of neuropathic pain, as well as the pharmacokinetics, drug-interaction potential, adverse effects, and dosing of these agents, with an emphasis on their use in older individuals."( Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain.
Guay, DR, 2003
)
1.76
"OXC, at a dosage of 900-1,200 mg/day, was administered for 5 consecutive weeks to 25 outpatients, 10 men and 15 women, aged 25 to 64 years, with bipolar or schizoaffective disorder."( Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine.
Cacciola, M; D'Arrigo, C; La Torre, D; Migliardi, G; Pacetti, M; Rosaria Muscatello, M; Spina, E; Zoccali, R, 2005
)
0.55
" Detoxification followed a predefined dosage scheme."( Scheme-based benzodiazepine detoxification with oxcarbazepine -- a case report.
Croissant, B; Diehl, A; Grosshans, M; Klein, O; Mann, K, 2005
)
0.58
" However, adverse event occurrence can be correlated to fluctuations in plasma drug levels that occur with varying dosing regimens of the many AEDs."( Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
Ahmad, A; Garnett, WR, 2005
)
0.59
" Clinical heterogeneity was assessed by reviewing differences across trials in characteristics of randomized patients, dosing protocols and trial design."( Oxcarbazepine versus phenytoin monotherapy for epilepsy.
Marson, AG; Muller, M; Williamson, PR, 2006
)
1.78
"A total of 116 outpatients 7 to 18 years of age with bipolar I disorder, manic or mixed, were recruited at 20 centers in the United States and randomly assigned to receive 7 weeks of double-blinded, flexibly dosed treatment with oxcarbazepine (maximum dose 900-2400 mg/day) or placebo."( A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents.
Berv, D; D'Souza, J; Emslie, GJ; Findling, RL; Kowatch, RA; Lehman, RB; Linden, D; McCague, K; Wagner, KD; Wamil, A; Wilens, TE, 2006
)
0.76
" For these older drugs it has been common practice to adjust the dosage to achieve a serum drug concentration within a predefined 'therapeutic range', representing an interval where most patients are expected to show an optimal response."( Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Johannessen, SI; Tomson, T, 2006
)
0.33
"OXC at a dosage of 1500-1800 mg/day might be beneficial in terms of alcohol relapse prevention."( High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients.
Andreoli, S; Di Nicola, M; Janiri, L; Martinotti, G; Moroni, N; Pozzi, G; Romanelli, R, 2007
)
0.66
" The discontinuation or dosage decrease of carbamazepine or oxcarbazepine may be associated with a slow increase of lamotrigine levels over several weeks and thus increase risk of lamotrigine toxicity that may manifest as oral ulcers."( Two case reports of oral ulcers with lamotrigine several weeks after oxcarbazepine withdrawal.
de Leon, J; O'Neill, A, 2007
)
0.82
" The mean dosage of OXC was 1033 mg daily."( Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study.
Mancardi, GL; Restivo, D; Solaro, C; Tanganelli, P, 2007
)
1.78
" More certainly, they minimise concentration-related adverse effects, and the dosing flexibility and consistency of plasma concentrations may simplify the management of antiepileptic drug therapy."( Extended-release formulations for the treatment of epilepsy.
Bialer, M, 2007
)
0.34
"Two spectrophotometric methods are proposed for the assay of oxcarbazepine (OXC) in bulk and dosage forms using Folin-Ciocalteu phenol reagent (FCP) and 3-methyl-2-benzothiazolinone hydrazine hydrochloride (MBTH) as reagents."( Use of Folin-Ciocalteu phenol reagent and 3-methyl-2-benzothiazolinone hydrazine hydrochloride in the determination of oxcarbazepine in pharmaceuticals.
Gandhimathi, M; Ravi, TK, 2008
)
0.8
"Drugs were tested in a repeated dosing paradigm (four daily injections)."( Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies.
Bennett, GJ; Naso, L; Xiao, W,
)
0.13
" The detoxification program followed an outlined dosage scheme with oxcarbazepine increase and benzodiazepine tapering."( Oxcarbazepine in rapid benzodiazepine detoxification.
Croissant, B; Diehl, A; Grosshans, M; Mann, K, 2008
)
2.02
"Oxcarbazepine is used in lower doses than recommended and the dosing is not adjusted for weight."( [Utilization of carbamazepine and oxcarbazepine in pediatric patients with partial epilepsy in Spain. An observational study].
Carreño, M; Rufo Campos, M,
)
1.85
" A significant decrease of ratio plasma concentration of 10-monohydroxy derivate (MHD) of oxcarbazepine to dosage was found by 26."( Seizure deterioration in women treated with oxcarbazepine during pregnancy.
Hansen-Schwartz, J; Petrenaite, V; Sabers, A, 2009
)
0.84
"In this 12 week, randomized, double-blind pilot study, 60 patients diagnosed with acute mania (DSM-IV) and a baseline Young Mania Rating Scale (YMRS) score of 20 or more received flexibly dosed oxcarbazepine (1,000-2,400 mg/day) or divalproex (750-2,000 mg/day)."( Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study.
Chopra, D; Gupta, NK; Kakkar, AK; Kataria, D; Rehan, HS; Unni, KE, 2009
)
0.82
" Fifty-one patients received carbamazepine as a monotherapy in dosage 300-1200 mg/day, 21 patients were treated with oxcarbazepine in dosage 600-1500 mg daily."( [Comparison of efficacy of trileptal (oxcarbazepine) and carbamazepine in the treatment of temporal epilepsy].
Basamygin, AV; Kalinin, VV; Polianskiĭ, DA; Sokolova, LV; Zemlianaia, AA; Zheleznova, EV, 2008
)
0.83
" Analysis of the log dose-response curves for oxcarbazepine or gabapentin in a presence of amitriptyline and oxcarbazepine or gabapentin applied alone, revealed a synergism in oxcarbazepine-amitriptyline and additivity in gabapentin-amitriptyline combination."( Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice.
Bosković, B; Micov, AM; Prostran, MS; Stepanović-Petrović, RM; Tomić, MA; Ugresić, ND; Vucković, SM, 2010
)
0.84
"The aim of this study was to characterize the anticonvulsant effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline (MeTHIQ--an endogenous parkinsonism-preventing substance) in combination with four second-generation antiepileptic drugs (AEDs: lamotrigine [LTG], oxcarbazepine [OXC], pregabalin [PGB], and topiramate [TPM]) in the mouse maximal electroshock (MES)-induced seizure model by using the type I isobolographic analysis for parallel and non-parallel dose-response relationship curves (DRRCs)."( Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis.
Antkiewicz-Michaluk, L; Czuczwar, SJ; Luszczki, JJ; Raszewski, G, 2010
)
0.77
"We administered oxcarbazepine at a dosage of 1200 mg/d, and this subject improved both in hair pulling and in eating behaviors with no relapse after 9 months."( Oxcarbazepine for the treatment of trichotillomania.
Gastaldi, F; Leombruni, P,
)
1.92
" In three trials, carbamazepine failed to reduce alcohol withdrawal symptoms possibly as a result of delayed administration, inadequate dosage or inadequate sample size."( The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome.
Barrons, R; Roberts, N, 2010
)
0.65
", lamotrigine [LTG], oxcarbazepine [OXC] and topiramate [TPM]) in the mouse maximal electroshock (MES)-induced seizure model by using the type I isobolographic analysis for non-parallel dose-response relationship curves (DRRCs)."( Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves.
Czuczwar, SJ; Filip, D; Luszczki, JJ, 2010
)
0.93
" Dosing and plasma levels of levetiracetam and concomitant antiepileptic drugs were reviewed retrospectively."( Age and comedications influence levetiracetam pharmacokinetics in children.
Dahlin, MG; Ohman, I; Wide, K, 2010
)
0.36
" The degree of decline in serum sodium concentration was significantly negatively correlated with the dosage of OXC."( Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy.
Chang, WN; Chuang, YC; Lai, SL; Lin, CH; Lu, CH; Tsai, MH; Tsai, NW; Tseng, YL; Wang, FJ,
)
0.48
" Therefore, the patient's daily dosage of oxcarbazepine and phenytoin were reduced."( Phenytoin toxicity secondary to an oxcarbazepine-phenytoin 2C19 interaction.
Kane, AJ; Soskin, DP; Stern, TA,
)
0.67
" In case of breakthrough seizures or increased seizure frequency, dosage adjustment of both drugs may be required."( Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy.
de Haan, GJ; Edelbroek, P; Lindhout, D; Sander, JW; Wegner, I, 2010
)
0.64
"0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132."( Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.
Almeida, L; Elger, C; Falcão, A; Halász, P; Perucca, E; Soares-da-Silva, P, 2011
)
0.37
" Mean dosage of oxcarbazepine was 1,230 mg/day (min 600, max 2,100 mg/day)."( Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life.
Dinapoli, L; Fabi, A; Maschio, M; Muti, P; Pace, A; Sperati, F; Vidiri, A, 2012
)
2.17
" Forty adult patients were studied and oxcarbazepine was administered orally at a single loading dosage of 30 mg/kg."( Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy.
Cho, JY; Chu, K; Gu, N; Jang, IJ; Kim, DW; Kim, HS; Lee, SK; Oh, J; Yoon, SH; Yu, KS, 2012
)
0.9
" LGI1 gene dosage was performed by real-time quantitative PCR (qPCR)."( LGI1 microdeletion in autosomal dominant lateral temporal epilepsy.
Barozzi, C; Cubeddu, T; de Falco, A; de Falco, FA; Errichiello, L; Fanciulli, M; Michelucci, R; Nobile, C; Rampazzo, A; Rigon, L; Santulli, L; Striano, P; Striano, S; Tomasi, L; Uzzau, S, 2012
)
0.38
" The smaller peak-to-trough fluctuation of eslicarbazepine in CSF (a measure of sustained delivery to the brain) than in plasma supports once-daily dosing of ESL."( Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.
Almeida, L; Falcão, A; Nunes, T; Rocha, JF; Soares-da-Silva, P, 2013
)
0.6
" The primary study variable was to assess the maximum tolerated dosage with OXC-MR and OXC-IR."( [Slow release versus immediate release oxcarbazepine in difficult-to-treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study].
Elger, CE; Hueber, R; Paulus, W; Schulze-Bonhage, A; Stefan, H; Steinhoff, BJ; Wangemann, M, 2012
)
0.65
" The initial dosage of 900 mg, 1,200 mg or 1,500 mg OXC was increased every 5 days by 300 mg up to a maximum daily dosage of 2,700 mg."( [Slow release versus immediate release oxcarbazepine in difficult-to-treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study].
Elger, CE; Hueber, R; Paulus, W; Schulze-Bonhage, A; Stefan, H; Steinhoff, BJ; Wangemann, M, 2012
)
0.65
" The maximum mean daily OXC dosage at the end of the study period was 1,950 mg with OXC-MR and thus statistically significantly higher than in OXC-IR group (1,650 mg, p = 0."( [Slow release versus immediate release oxcarbazepine in difficult-to-treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study].
Elger, CE; Hueber, R; Paulus, W; Schulze-Bonhage, A; Stefan, H; Steinhoff, BJ; Wangemann, M, 2012
)
0.65
" In spite of a higher mean daily dosage adverse events and especially CNS-related adverse events occurred less often than with OXC-IR."( [Slow release versus immediate release oxcarbazepine in difficult-to-treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study].
Elger, CE; Hueber, R; Paulus, W; Schulze-Bonhage, A; Stefan, H; Steinhoff, BJ; Wangemann, M, 2012
)
0.65
" Mean PGB dosage was 279 mg/day."( Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study.
Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012
)
0.38
" We planned to include trials of oxcarbazepine compared with placebo or any other intervention, regardless of administration route, dosage or length of treatment."( Oxcarbazepine for neuropathic pain.
Chen, N; He, L; Wu, F; Yang, M; Zhou, M; Zhu, C, 2013
)
2.11
" The mean area under the curve (AUC)ss,0-τ (in μmol h/L) following the last dose of an 8-day repeated dosing was 1156."( Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.
Almeida, L; Bialer, M; Elger, C; Falcão, A; Nunes, T; Soares-da-Silva, P; Vaz-da-Silva, M, 2013
)
0.63
"Oral loading of oxcarbazepine suspension followed by maintenance dosing is well tolerated and effective in steadily achieving the therapeutic level of MHD in selected patients with epilepsy."( Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
Cho, JY; Chu, K; Gu, N; Jang, IJ; Kim, DW; Lee, H; Lee, SK; Na, HJ; Yoon, SH; Yu, KS, 2013
)
1.02
" Once-daily dosing was not associated with any new safety signals."( Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial.
Baroldi, P; Brittain, ST; French, JA; Johnson, JK, 2014
)
0.67
" Comparisons were made between the groups based on the age of onset, seizure frequency before treatment, time interval between seizure onset and treatment start, time interval between the two EEGs, oxcarbazepine dosage at the follow-up electroencephalography, occurrence of daytime seizures, and seizure control."( Changes in current-source density of interictal spikes in benign epilepsy of childhood with centrotemporal spikes following treatment with oxcarbazepine.
Jung, S; Kim, YS; Kwon, OY; Yeom, JS, 2014
)
0.79
" This model may be very useful for establishing individual dosage guidelines of OXC in Chinese children with epilepsy."( Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Liu, ZS; Peng, J; Wang, Y; Xu, H; Zhang, HN, 2014
)
0.69
"6 months, 27% of responders to CBZ incurred in undesired effects to a level that caused interruption of treatment or a dosage reduction to an unsatisfactory level."( Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain.
Cruccu, G; Di Stefano, G; La Cesa, S; Truini, A, 2014
)
0.61
"Nineteen patients completed the desensitization protocol to a target dosage over 2-5 months."( Human leukocyte antigen genotypes and trial of desensitization in patients with oxcarbazepine-induced skin rash: a pilot study.
Kang, ES; Lee, B; Lee, J; Lee, M; Yu, HJ, 2014
)
0.63
" The final PPK model was demonstrated to be suitable and effective and it can be used to evaluate the pharmacokinetic parameters of MHD in Chinese patients with epilepsy and to choose an optimal dosage regimen of oxcarbazepine on the basis of these parameters."( Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
Hao, G; Lv, C; Xu, W; Yu, Y; Zhang, Q, 2016
)
0.89
" Hence, oxcarbazepine can be generally applied using the same dosage and administration for the treatment of partial onset seizures in pediatric patients, regardless of ethnicity."( Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
Bouillon, T; Fink, M; Hirota, T; Sugiyama, I; Suzuki, H; Yamaguchi, M, 2015
)
1.09
"To assess efficacy/tolerability of ezogabine (EZG)/retigabine (RTG) in combination with specified monotherapy antiepileptic drug (AED) treatments in adults with uncontrolled partial-onset seizures using a flexible dosing regimen."( Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.
Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015
)
0.42
"NCT01227902 was an open-label, uncontrolled study of flexibly dosed EZG/RTG."( Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.
Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015
)
0.42
"EZG/RTG was effective as adjunctive therapy to CBZ/OXC, LTG, LEV, and VPA, using a flexible dosing regimen, in adults with partial-onset seizures; safety and tolerability were consistent with that previously observed."( Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.
Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015
)
0.42
"The occurrence of AEs is significantly (and non-linearly) dependent on MHD serum level, whereas the dependence of OXC dosage is less distinctive."( Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
May, TW; Sattler, A; Schaefer, M, 2015
)
0.63
" This population PK model can be applied for optimizing topiramate dosage regimens in actual clinical practice."( Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis.
Bae, EK; Jang, IJ; Kim, TJ; Lee, J; Lee, KJ; Lee, SK; Moon, J; Shin, D; Shin, JW; Shin, YW, 2016
)
0.43
" Patients were switched because they experienced persistent seizures with OXC but were unable to tolerate increased OXC dosing due to adverse events."( Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study.
Höfler, J; Kalss, G; Kirschner, M; Kuchukhidze, G; Leitinger, M; Rohracher, A; Schmid, E; Steinhoff, BJ; Trinka, E; Wendling, AS, 2017
)
0.76
" This improvement is more pronounced if the OXC-related AEs are most evident following morning dosing of OXC."( Transition from oxcarbazepine to eslicarbazepine acetate: A single center study.
Mäkinen, J; Peltola, J; Rainesalo, S, 2017
)
0.8
"Co-administration of dolutegravir and oxcarbazepine has been reported to reduce levels of dolutegravir and therefore is contraindicated due to insufficient data to make dosing recommendations."( Sustained viral suppression with co-administration of oxcarbazepine and dolutegravir.
Badowski, ME; Kandil, MM; Schriever, CA, 2018
)
1
" Oxcarbazepine dosage was found to linearly correlate with AEP and ABNAS scores, better than carbamazepine dosage."( Adverse effects of anti-epileptics in trigeminal neuralgiform pain.
Cregg, R; Lee, G; O'Keeffe, AG; Reading, J; Tentolouris-Piperas, V; Zakrzewska, JM, 2018
)
1.39
"The present investigation was undertaken with an objective of formulating sustained release microspheres of oxcarbazepine (OXC), an anti-epileptic drug, to overcome poor patient compliance and exposure to high doses associated with currently marketed OXC dosage forms."( COLOCASIA ESCULENTA CORMS MUCILAGE-ALGINATE MICROSPHERES OF OXCARBAZEPINE: DESIGN, OPTIMIZATION AND EVALUATION.
Ahmad, J; Bashir, S; Ghumman, SA; Hameed, H; Khan, IU, 2017
)
0.91
"Evidence for the comparative teratogenic risk of antiepileptic drugs is insufficient, particularly in relation to the dosage used."( Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.
Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Thomas, SV; Tomson, T; Vajda, F, 2018
)
0.48
" When sodium channel blockers cannot reach full dosage because of side effects, an add-on treatment with lamotrigine or baclofen should be considered."( Current and Innovative Pharmacological Options to Treat Typical and Atypical Trigeminal Neuralgia.
Cruccu, G; Di Stefano, G; Truini, A, 2018
)
0.48
" A new dosing strategy combining the dosage guideline and Bayesian method is proposed to individualise OXC regimens."( Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
Jiao, Z; Li, XW; Lin, WW; Lin, XH; Rao, X; Wang, CL; Zeng, DY; Zhang, J, 2019
)
0.8
"A PPK model was established to estimate individual MHD clearance in paediatric patients taking OXC to develop individualised OXC dosing regimens for Chinese paediatric epilepsy patients."( Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
Jiao, Z; Li, XW; Lin, WW; Lin, XH; Rao, X; Wang, CL; Zeng, DY; Zhang, J, 2019
)
0.8
" This study established a population pharmacokinetic (PPK) model of MHD in Chinese children with epilepsy and conducted a dosage simulation in order to provide support for individualized OXC treatment."( Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy.
Chen, CY; Cui, YM; Wu, Y; Yang, T; Zhao, X; Zhou, Y, 2019
)
0.77
" A priori dosing guideline was proposed considering WT and MHD plasma concentrations, providing a basis for OXC dosage calculations and adjustments in Chinese epileptic children."( Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy.
Chen, CY; Cui, YM; Wu, Y; Yang, T; Zhao, X; Zhou, Y, 2019
)
0.77
" In the clinical setting, these findings can help to estimate LTG concentrations and adjust dosage and evaluate adverse drug reactions."( The influence of concomitant antiepileptic drugs on lamotrigine serum concentrations in Northwest Chinese Han population with epilepsy.
Han, X; Huang, J; Lv, J; Ma, L; Nie, X; Peng, L; Wang, J; Xia, L; Zan, X, 2019
)
0.51
" The MHD plasma concentration was detected by high-performance liquid chromatography and then standardized through dosage and body weight."( Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms.
Chen, X; Fang, S; Gong, Z; Ma, H; Qian, L; Wei, J; Xu, Z; Yan, Y; Yang, X; Zeng, S, 2019
)
0.87
" The aim of this study was to establish a PPK model of MHD to investigate the effects of genetic polymorphisms in UGT2B7, UGT1A9, ABCB1, and ABCB2 in adult Chinese patients with epilepsy and to develop a new dosage guideline for OXC."( Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis.
Jiao, Z; Lin, RF; Lin, S; Lin, WW; Lin, XH; Wang, CL; Yu, XL; Zhang, J; Zhang, WB, 2019
)
0.75
" Moreover, a new dosage guideline was proposed based on the final model to individualize OXC regimens for adult patients with varying BW and renal function."( Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis.
Jiao, Z; Lin, RF; Lin, S; Lin, WW; Lin, XH; Wang, CL; Yu, XL; Zhang, J; Zhang, WB, 2019
)
0.75
"6%), major side effects caused treatment interruption or dosage reduction to an unsatisfactory level."( Real-world effectiveness and tolerability of carbamazepine and oxcarbazepine in 354 patients with trigeminal neuralgia.
Cruccu, G; De Stefano, G; Di Lionardo, A; Di Pietro, G; Di Stefano, G; Leone, C; Mollica, C; Sgro, E; Truini, A, 2021
)
0.86
" The quality of the retrieved studies was evaluated, and significant covariates that may have an impact on the dosage regimen of oxcarbazepine were explored."( Population pharmacokinetics of oxcarbazepine: a systematic review.
Chen, YT; Jiao, Z; Li, ZR; Lin, WW; Wang, CY; Yin, YW; Zhu, M, 2021
)
1.11
" Because limited information is available for exposure-response relationship, additional pharmacokinetic/pharmacodynamics investigations of oxcarbazepine need to be conducted to optimize the dosage regimen in clinical practice."( Population pharmacokinetics of oxcarbazepine: a systematic review.
Chen, YT; Jiao, Z; Li, ZR; Lin, WW; Wang, CY; Yin, YW; Zhu, M, 2021
)
1.11
"Poor bioavailability is a major obstacle in the development of an effective dosage form of the poorly soluble drugs."( Improved bioavailability of oxcarbazepine, a BCS class II drug by centrifugal melt spinning: In-vitro and in-vivo implications.
Abbas, N; Arshad, MS; Bukhari, NI; Hussain, A; Hussain, F; Nasir, S, 2021
)
0.92
" Exposure to certain newer ASMs, such as lamotrigine and levetiracetam, does not thus far appear to impact certain aspects of neurodevelopment, but further delineation across the different neurodevelopmental domains and dosage levels is required."( Neurodevelopmental outcomes in children exposed to newer antiseizure medications: A systematic review.
Bromley, RL; Knight, R; Wittkowski, A, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anticonvulsantA drug used to prevent seizures or reduce their severity.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dibenzoazepine
cyclic ketone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Carbamazepine Metabolism Pathway718

Protein Targets (47)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency16.77610.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency26.96800.177814.390939.8107AID2147
phosphopantetheinyl transferaseBacillus subtilisPotency41.21320.141337.9142100.0000AID1490; AID2701
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID504865
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
TDP1 proteinHomo sapiens (human)Potency26.10110.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency33.49150.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency35.63830.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency22.40470.001022.650876.6163AID1224838; AID1224893
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency10.00000.28189.721235.4813AID2326
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency22.38720.540617.639296.1227AID2528
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency50.11870.354828.065989.1251AID504847
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency12.60820.000323.4451159.6830AID743065; AID743067
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency44.66840.010323.856763.0957AID2662
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency33.49830.004611.374133.4983AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency35.48130.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.18110.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
polyadenylate-binding protein 1Homo sapiens (human)IC50 (µMol)47.05004.910023.702976.1900AID602259; AID602260
bcl-2-related protein A1Mus musculus (house mouse)IC50 (µMol)100.00000.41907.756335.1000AID432; AID621
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
P2X purinoceptor 4Homo sapiens (human)IC50 (µMol)10.00000.15602.93526.1000AID1064727
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (77)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
regulation of ruffle assemblyP2X purinoceptor 4Homo sapiens (human)
tissue homeostasisP2X purinoceptor 4Homo sapiens (human)
regulation of sodium ion transportP2X purinoceptor 4Homo sapiens (human)
response to ischemiaP2X purinoceptor 4Homo sapiens (human)
signal transductionP2X purinoceptor 4Homo sapiens (human)
regulation of blood pressureP2X purinoceptor 4Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 4Homo sapiens (human)
negative regulation of cardiac muscle hypertrophyP2X purinoceptor 4Homo sapiens (human)
neuronal action potentialP2X purinoceptor 4Homo sapiens (human)
sensory perception of painP2X purinoceptor 4Homo sapiens (human)
calcium-mediated signalingP2X purinoceptor 4Homo sapiens (human)
positive regulation of prostaglandin secretionP2X purinoceptor 4Homo sapiens (human)
response to ATPP2X purinoceptor 4Homo sapiens (human)
monoatomic ion transmembrane transportP2X purinoceptor 4Homo sapiens (human)
response to fluid shear stressP2X purinoceptor 4Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 4Homo sapiens (human)
endothelial cell activationP2X purinoceptor 4Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationP2X purinoceptor 4Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processP2X purinoceptor 4Homo sapiens (human)
behavioral response to painP2X purinoceptor 4Homo sapiens (human)
response to axon injuryP2X purinoceptor 4Homo sapiens (human)
positive regulation of calcium-mediated signalingP2X purinoceptor 4Homo sapiens (human)
regulation of chemotaxisP2X purinoceptor 4Homo sapiens (human)
sensory perception of touchP2X purinoceptor 4Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionP2X purinoceptor 4Homo sapiens (human)
membrane depolarizationP2X purinoceptor 4Homo sapiens (human)
positive regulation of calcium ion transportP2X purinoceptor 4Homo sapiens (human)
regulation of cardiac muscle contractionP2X purinoceptor 4Homo sapiens (human)
relaxation of cardiac muscleP2X purinoceptor 4Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 4Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 4Homo sapiens (human)
cellular response to zinc ionP2X purinoceptor 4Homo sapiens (human)
cellular response to ATPP2X purinoceptor 4Homo sapiens (human)
apoptotic signaling pathwayP2X purinoceptor 4Homo sapiens (human)
positive regulation of microglial cell migrationP2X purinoceptor 4Homo sapiens (human)
positive regulation of endothelial cell chemotaxisP2X purinoceptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (32)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 4Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 4Homo sapiens (human)
signaling receptor bindingP2X purinoceptor 4Homo sapiens (human)
copper ion bindingP2X purinoceptor 4Homo sapiens (human)
protein bindingP2X purinoceptor 4Homo sapiens (human)
ATP bindingP2X purinoceptor 4Homo sapiens (human)
zinc ion bindingP2X purinoceptor 4Homo sapiens (human)
identical protein bindingP2X purinoceptor 4Homo sapiens (human)
cadherin bindingP2X purinoceptor 4Homo sapiens (human)
ligand-gated calcium channel activityP2X purinoceptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
lysosomal membraneP2X purinoceptor 4Homo sapiens (human)
plasma membraneP2X purinoceptor 4Homo sapiens (human)
membraneP2X purinoceptor 4Homo sapiens (human)
cell junctionP2X purinoceptor 4Homo sapiens (human)
neuronal cell bodyP2X purinoceptor 4Homo sapiens (human)
terminal boutonP2X purinoceptor 4Homo sapiens (human)
dendritic spineP2X purinoceptor 4Homo sapiens (human)
cell bodyP2X purinoceptor 4Homo sapiens (human)
perinuclear region of cytoplasmP2X purinoceptor 4Homo sapiens (human)
extracellular exosomeP2X purinoceptor 4Homo sapiens (human)
plasma membraneP2X purinoceptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (113)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1220844Cmax in human at 300 mg, po administered as one-film coated tablet by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1064727Antagonist activity at human P2X4 receptor expressed in human 1321N1 cells assessed as inhibition of ATP-induced cytosolic calcium influx preincubated for 30 mins followed by ATP addition by Fluo-4 AM dye-based fluorescence assay2014Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3
Carbamazepine derivatives with P2X4 receptor-blocking activity.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID178166Compound was tested for anticonvulsant activity administered by gastric tube in rat by MES test1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID539470Solubility of the compound in water2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID196514t max was for the anticonvulsant effect was tested in rats administered by gastric tube; t max1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID1220860n-Octanol/aqueous buffer partition coefficient, log P of the compound at pH 7.42011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220857Oral bioavailability in human at 300 mg administered as one-film coated tablet by non-enantiospecific assay based high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1220843Tmax in human at 300 mg, po administered as one-film coated tablet by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1220855AUC in human at 300 mg, po administered as one-film coated tablet by non-enantiospecific assay based high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID189164Protective index value of the compound, given by intraperitoneally (TD50/ED50)1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID196513t max for anticonvulsant activity was tested in rats intraperitoneally1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID195317Compound was tested for anticonvulsant activity against MES-induced seizures in rat1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID190105Compound was tested for anticonvulsant activity administered by gastric tube in rat by rotarod test1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID1220833Tmax in human treated with monohydroxy derivative of OXC at 250 mg, iv administered as infusion over 30 mins by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1064726Antagonist activity at human P2X4 receptor expressed in human 1321N1 cells assessed as inhibition of ATP-induced cytosolic calcium influx at 10 uM preincubated for 30 mins followed by ATP addition by Fluo-4 AM dye-based fluorescence assay2014Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3
Carbamazepine derivatives with P2X4 receptor-blocking activity.
AID189163Protective index value of the compound, given by gastric tube (TD50/ED50)1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID1220836AUC in human treated with monohydroxy derivative of OXC at 250 mg, iv administered as infusion over 30 mins by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID194782Percent inhibition of 22Na+ uptake by voltage sensitive sodium channel of rat cortical synaptosomes at 100 uM1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID176347Compound was tested intraperitoneally for anticonvulsant activity against MES-induced seizures in rat by MES test1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID190110Compound was tested intraperitoneally for anticonvulsant activity by rotarod test1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID1220834Cmax in human treated with monohydroxy derivative of OXC at 250 mg, iv administered as infusion over 30 mins by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID194783Percent inhibition of 22Na+ uptake by voltage sensitive sodium channel of rat cortical synaptosomes at 30 uM1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID217795Displacement of [3H]BTX from voltage-gated sodium channel of rat cortical synaptosomes1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1220845AUC in human at 300 mg, po administered as one-film coated tablet by high-performance liquid chromatography2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1220858Drug level in human plasma at 400 mg, po2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID194785Percent inhibition of 22Na+ uptake by voltage sensitive sodium channel of rat cortical synaptosomes at 300 uM1999Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14
Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409600Inhibition of human aquaporin 4 M23 isoform expressed in Xenopus laevis oocytes at 20 uM2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Inhibition of aquaporin 4 by antiepileptic drugs.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID652178Confirmed Agonists of Novel Allosteric Modulators of the M1 Muscarinic Receptor2013Molecules (Basel, Switzerland), Jan-08, Volume: 18, Issue:1
Benchmarking ligand-based virtual High-Throughput Screening with the PubChem database.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,135)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (2.47)18.7374
1990's112 (9.87)18.2507
2000's463 (40.79)29.6817
2010's402 (35.42)24.3611
2020's130 (11.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 111.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index111.39 (24.57)
Research Supply Index7.23 (2.92)
Research Growth Index5.26 (4.65)
Search Engine Demand Index205.77 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (111.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials170 (14.01%)5.53%
Reviews191 (15.75%)6.00%
Case Studies254 (20.94%)4.05%
Observational20 (1.65%)0.25%
Other578 (47.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (52)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicentre, Open-label, Extension Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy [NCT01051193]Phase 2/Phase 388 participants (Actual)Interventional2010-01-05Completed
A Multicenter, Open-label, Parallel-group Study in Study Participants With Epilepsy, to Evaluate the Effect of Oxcarbazepine on the Pharmacokinetics, Safety, and Tolerability of Padsevonil [NCT03695094]Phase 131 participants (Actual)Interventional2018-09-18Completed
Efficacy and Tolerability of Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy (STANDLOW). A Multicenter, Randomized, Single-blind, Parallel-group Trial [NCT03689114]Phase 4374 participants (Anticipated)Interventional2020-01-07Not yet recruiting
A Multi-center, Randomized, Double-blind, Parallel Group, Placebo-controlled 52 Weeks Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o.(300-1200 mg/Day) as Adjuvant Therapy in the Bipolar Disorder I or II Treatment [NCT00154323]Phase 455 participants (Actual)Interventional2003-01-31Completed
Pilot Study of Oxtellar XR (Oxcarbazepine Extended Release) in Neurology Patients With Trigeminal Neuralgia [NCT03374709]Phase 40 participants (Actual)Interventional2018-12-14Withdrawn(stopped due to Resource and time constraints were encountered by product manufacturer and study team.)
Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers [NCT01679002]Phase 112 participants (Actual)Interventional2003-10-31Completed
Symptom-Based Treatment for Neuropathic Pain in Spinal Cord Injured Patients, Randomized Clinical Trial [NCT02180880]Phase 463 participants (Actual)Interventional2012-11-30Completed
An Exploratory Randomized Open Comparison of Oxtellar XR® vs Oxcarbazepine IR (Trileptal®) for the Treatment of Bipolar Depression [NCT03567681]Phase 4120 participants (Anticipated)Interventional2018-06-13Enrolling by invitation
A Single-Dose, Comparative Bioavailability Study of Two Formulations of Oxcarbazepine 600 mg Tablets Under Fasting Conditions [NCT00850174]Phase 160 participants (Actual)Interventional2005-04-30Completed
Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain: Predictors of Response - a Randomised, Double-blind, Placebo-controlled Clinical Trial [NCT01302275]Phase 4117 participants (Actual)Interventional2011-02-28Completed
Long Term Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy [NCT00918424]0 participants Expanded Access2009-06-30Approved for marketing
A Phase Ib Study of Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain [NCT02078089]Phase 11 participants (Actual)Interventional2014-03-06Terminated(stopped due to Poor Accrual)
OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial [NCT02104661]Phase 230 participants (Actual)Interventional2014-10-31Completed
Characterization of Epilepsy Patients At-risk for Adverse Outcomes Related to Switching Antiepileptic Drug Products: BEEP 2b Study [NCT02707965]Phase 121 participants (Actual)Interventional2017-06-08Completed
The Efficacy and Safety of First-Line Anti-Epileptic Drugs (AEDs) as Substitution Therapy in Children Who Are Resistant to Second-Line AEDs [NCT05697614]Phase 4100 participants (Anticipated)Interventional2023-03-01Recruiting
An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioavailability Study Comparing Oxcarbazepine 300 mg/5mL Oral Suspension of OHM Laboratories (a Subsidiary of Ranbaxy Pharmaceuticals Inc) With Trileptal® [NCT00951600]40 participants (Actual)Interventional2006-09-30Completed
An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioavailability Study Comparing Oxcarbazepine 300 mg/5mL Oral Suspension of OHM Laboratories (a Subsidiary of Ranbaxy Pharmaceuticals Inc.) With Trileptal [NCT00951847]40 participants (Actual)Interventional2006-10-31Completed
Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures [NCT02705768]Phase 490 participants (Actual)Interventional2016-04-30Completed
A 24-Week Prospective, Open-Label, Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Adult Patients With Partial Seizures [NCT00275925]Phase 480 participants Interventional2005-12-31Completed
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions [NCT01703468]Phase 159 participants (Actual)Interventional2009-09-30Completed
Safety and Efficacy of a Novel Modified Release Formulation of Oxcarbazepine (OXC MR) vs an Immediate Release Oxcarbazepine (OXC IR) Product in Patients With Partial Epilepsy [NCT00391534]Phase 3100 participants (Anticipated)Interventional2006-10-31Terminated(stopped due to Low recruitment rate)
Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy [NCT00918047]Phase 118 participants (Actual)Interventional2009-06-30Completed
Oxcarbazepine Versus Placebo in Childhood Autism [NCT00467753]5 participants (Actual)Interventional2006-04-30Completed
Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase [NCT01893229]Phase 4120 participants (Anticipated)Interventional2013-09-30Recruiting
Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia [NCT00637234]Phase 2/Phase 354 participants (Actual)Interventional2004-07-31Completed
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies [NCT02893371]1,037,352 participants (Actual)Observational2016-09-30Completed
A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fasting Conditions [NCT00616681]28 participants (Actual)Interventional2004-06-30Completed
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions [NCT00618046]48 participants (Actual)Interventional2004-11-30Completed
Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy [NCT00908349]Phase 3214 participants (Actual)Interventional2009-06-30Completed
Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures [NCT00772603]Phase 3366 participants (Actual)Interventional2008-11-30Completed
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Oxcarbazapine 600 mg Tablets Under Fed Conditions [NCT00616863]28 participants (Actual)Interventional2004-07-31Completed
A Phase I, Single Centre, Open, Randomised, Parallel Study to Evaluate the Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine in Healthy Subject [NCT00900237]Phase 114 participants (Actual)Interventional2008-11-30Completed
Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Double-Blind, Randomized Clinical Effectiveness Study. [NCT02219373]Phase 360 participants (Anticipated)Interventional2023-08-31Not yet recruiting
A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg/Day) as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents [NCT00154362]Phase 450 participants (Actual)Interventional2003-04-30Completed
Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Oxcarbazepine Efficacy in Asthma Therapy [NCT00142025]Phase 455 participants Interventional2001-09-30Completed
The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) - An Eight Week Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi Center Trial. A Phase III Study [NCT00145691]Phase 3100 participants Interventional2005-09-30Completed
A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Monotherapy in Pediatric Patients With Inadequately-controlled Partial Seizures. [NCT00050947]Phase 394 participants (Actual)Interventional2002-07-31Completed
A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures [NCT00275912]Phase 460 participants (Actual)Interventional2006-09-11Completed
A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures. [NCT00050934]Phase 3132 participants (Actual)Interventional2002-06-30Completed
Induction of Drug Metabolism: A Comparative, Pharmacokinetic in Vivo Study of the Effect of Carbamazepine and Oxcarbazepine on CYP3A4. [NCT00260247]Phase 410 participants (Actual)Interventional2005-04-30Completed
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions [NCT01702623]Phase 164 participants (Actual)Interventional2009-09-30Completed
Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers [NCT01678976]Phase 113 participants (Actual)Interventional2002-03-31Completed
Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - Clinical Characteristics, Neuroanatomical Abnormalities and Treatment Efficacy [NCT04371575]60 participants (Actual)Observational2012-09-01Completed
Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database [NCT01390909]12,386 participants (Actual)Observational2010-05-31Completed
Comparative Efficacy of Carbamazepine Versus Oxcarbazepine in Treatment of Trigeminal Neuralgia- a Randomized Controlled Clinical Study [NCT04996199]Phase 4132 participants (Anticipated)Interventional2021-09-18Recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
Population Pharmacokinetics of Antiepileptic in Pediatrics [NCT03196466]1,000 participants (Anticipated)Observational2017-06-19Recruiting
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE) [NCT01891890]Phase 372 participants (Actual)Interventional2013-08-31Terminated(stopped due to Poor recruitment)
Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Oxcarbazepine 600 mg Tablet and Trileptal® Following a 600 mg Dose in Healthy Subjects Under Fed Conditions [NCT00849797]Phase 1120 participants (Actual)Interventional2005-07-31Completed
Electroclinical Effect of Steroid in Patients With Benign Childhood Epilepsy With Centrotemporal Spikes [NCT03490487]Phase 4100 participants (Anticipated)Interventional2018-06-20Recruiting
A Multi-Center, Open-label, Randomized Study to Evaluate the Long Term Effectiveness of Levetiracetam as Monotherapy in Comparison With Oxcarbazepine in Subjects With Newly or Recently Diagnosed Partial Epilepsy [NCT01498822]Phase 4353 participants (Actual)Interventional2011-06-30Completed
Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder [NCT02456896]Phase 450 participants (Actual)Interventional2015-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00772603 (5) [back to overview]PCH(T), ITT
NCT00772603 (5) [back to overview]Responder Rate, ITT
NCT00772603 (5) [back to overview]Seizure-Free Rates, ITT
NCT00772603 (5) [back to overview]Seizure Free Rate, ITT, (M)
NCT00772603 (5) [back to overview]PCH(M)- ITT
NCT00849797 (6) [back to overview]Cmax - Maximum Observed Concentration - Oxcarbazepine in Plasma
NCT00849797 (6) [back to overview]Cmax - 10-hydroxy-carbazepine in Plasma
NCT00849797 (6) [back to overview]AUC0-t - 10-Hydroxy-Carbazepine Metabolite
NCT00849797 (6) [back to overview]AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Oxcarbazepine
NCT00849797 (6) [back to overview]AUC0-inf - 10-Hydroxy-Carbazepine Metabolite
NCT00849797 (6) [back to overview]AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Oxcarbazepine
NCT00850174 (6) [back to overview]AUC0-inf - 10-hydroxy-carbazepine Metabolite
NCT00850174 (6) [back to overview]AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Oxcarbazepine
NCT00850174 (6) [back to overview]AUC0-t - 10-hydroxy-carbazepine Metabolite
NCT00850174 (6) [back to overview]AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Oxcarbazepine
NCT00850174 (6) [back to overview]Cmax - 10-hydroxy-carbazepine in Plasma
NCT00850174 (6) [back to overview]Cmax - Maximum Observed Concentration - Oxcarbazepine in Plasma
NCT00900237 (2) [back to overview]Cmax - Maximum Plasma Concentration in Plasma and Cerebral Spinal Fluid
NCT00900237 (2) [back to overview]AUC0-t AUC From Time Zero to the Last Sampling Time
NCT00908349 (1) [back to overview]Percent Change in Seizure Rate
NCT01390909 (1) [back to overview]Average Annualized Costs
NCT01498822 (4) [back to overview]Time to the First Seizure Defined as the Time From the First Dose of Medication to the Occurrence of the First Seizure During the 48 Weeks Treatment Period
NCT01498822 (4) [back to overview]Percentage of Subjects With a Treatment Failure
NCT01498822 (4) [back to overview]Percentage of Subjects Who Achieved Seizure Freedom for 24 Consecutive Weeks During the 48 Weeks Treatment Period at Any Time
NCT01498822 (4) [back to overview]Percentage of Subjects Who Achieved Seizure Freedom During the 48 Weeks Treatment Period
NCT01678976 (3) [back to overview]Total of Subjects Reporting at Least One Adverse Event
NCT01678976 (3) [back to overview]Maximum Drug Concentration (Cmax)
NCT01678976 (3) [back to overview]Area Under the Plasma Concentration Versus Time Curve (AUC)
NCT01679002 (3) [back to overview]AUC - Area Under the Plasma Concentration Versus Time Curve
NCT01679002 (3) [back to overview]Number of of Subjects Reporting at Least One Adverse Event
NCT01679002 (3) [back to overview]Cmax - Maximum Observed Plasma Drug Concentration
NCT01891890 (11) [back to overview]Wechsler Intelligence Scale for Children-IV Processing Speed
NCT01891890 (11) [back to overview]Pediatric Neuro-QOL Score
NCT01891890 (11) [back to overview]Affective Reactivity Scale
NCT01891890 (11) [back to overview]Child Behavior Checklist
NCT01891890 (11) [back to overview]Conners' Continuous Performance Test II (CPT-II) Confidence Index
NCT01891890 (11) [back to overview]Grooved Pegboard
NCT01891890 (11) [back to overview]Parenting Stress Inventory Short Form (PSI-4-SF)
NCT01891890 (11) [back to overview]Pediatric Inventory for Parents
NCT01891890 (11) [back to overview]Story Memory
NCT01891890 (11) [back to overview]Symbol Digit Modalities Test
NCT01891890 (11) [back to overview]The Number of Participants With a Positive Response on the Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT02456896 (2) [back to overview]Change in Serum Brain Derived Neurotrophic Factor (BDNF)
NCT02456896 (2) [back to overview]Correlation Between Young Mania Rating Scale (YMRS) and Serum Brain Derived Neurotrophic Factor (BDNF)
NCT02707965 (5) [back to overview]Mean Cmax_ss (Test vs. Reference)
NCT02707965 (5) [back to overview]Mean AUC0-last_ss (Test vs. Reference)
NCT02707965 (5) [back to overview]Number of Adverse Events
NCT02707965 (5) [back to overview]Number of Seizures Reported
NCT02707965 (5) [back to overview]Mean Cmin_ss (Test vs. Reference)
NCT03695094 (15) [back to overview]Percentage of Participants With at Least One Serious Adverse Event (SAE) During the Study
NCT03695094 (15) [back to overview]The Maximum Observed Plasma Concentration (Cmax) of Padsevonil (PSL) During the Study
NCT03695094 (15) [back to overview]Trough Plasma Concentration of Mono Hydroxy Derivate (MHD) in the Inducers Group Before, During and After Dosing to Steady State With PSL
NCT03695094 (15) [back to overview]The Time to Reach Maximum Concentration (Tmax) for UCB1431322-000 During the Study
NCT03695094 (15) [back to overview]The Time to Reach Maximum Concentration (Tmax) for UCB1447499-000 During the Study
NCT03695094 (15) [back to overview]The Time to Reach Maximum Concentration (Tmax) for Padsevonil During the Study
NCT03695094 (15) [back to overview]The Ratio of PSL Metabolite UCB1447499-000 to PSL Based on the Area Under the Curve (AUCtau)
NCT03695094 (15) [back to overview]The Ratio of PSL Metabolite UCB1431322-000 to PSL Based on the Area Under the Curve (AUCtau) During the Study
NCT03695094 (15) [back to overview]Percentage of Participants With at Least One Adverse Event (AE) During the Study
NCT03695094 (15) [back to overview]The Maximum Observed Plasma Concentration (Cmax) for UCB1447499-000 During the Study
NCT03695094 (15) [back to overview]The Maximum Observed Plasma Concentration (Cmax) for UCB1431322-000 During the Study
NCT03695094 (15) [back to overview]The Area Under the Plasma Concentration Time Curve (AUCtau) Over a Dosing Interval for PSL
NCT03695094 (15) [back to overview]The Area Under the Curve (AUCtau) Over a Dosing Interval for UCB1447499-000 During the Study
NCT03695094 (15) [back to overview]The Area Under the Curve (AUCtau) Over a Dosing Interval for UCB1431322-000 During the Study
NCT03695094 (15) [back to overview]The Apparent Total Plasma Clearance at Steady-state (CL/Fss) for PSL During the Study

PCH(T), ITT

Percent change (PCH) in seizure frequency per 28d relative to Baseline, Treatment Phase (PCH[T]), Intent-to-Treat population. (NCT00772603)
Timeframe: Change at 16 weeks (4wks Titration + 12 wks Maintenance) compared to Baseline

Interventionpercentage of change (Median)
2400mg/Day SPN-804-42.90
1200mg/Day SPN-804-38.20
Placebo-28.70

[back to top]

Responder Rate, ITT

Percent of patients with a positive response, defined as a 50% or greater reduction in seizure frequency per 28 days relative to Baseline, Treatment Phase, Intent-to-Treat population (NCT00772603)
Timeframe: At the end of 16 weeks (4 wks Titration + 12 wks Maintenance)

Interventionpercentage of patients (Number)
2400mg/Day SPN-80450
1200mg/Day SPN-80444
Placebo34

[back to top]

Seizure-Free Rates, ITT

Percent of patients seizure-free during Treatment Phase, Intent-to-Treat population (NCT00772603)
Timeframe: At the end of 16 weeks (4 wks Titration + 12 wks Maintenance)

Interventionpercentage of patients (Number)
2400mg/Day SPN-80414
1200mg/Day SPN-8046
Placebo4

[back to top]

Seizure Free Rate, ITT, (M)

Percent of patients seizure-free during Maintenance, Intent-to-Treat population (NCT00772603)
Timeframe: At the end of 12 weeks (Maintenance Period)

Interventionpercentage of patients (Number)
2400mg/Day SPN-80417
1200mg/Day SPN-8044
Placebo7

[back to top]

PCH(M)- ITT

Percent change in seizure frequency per 28 days relative to Baseline, Maintenance Period (PCH[M]), Intent-to-Treat population (NCT00772603)
Timeframe: Change at 12 weeks (Maintenance Period) compared to Baseline

Interventionpercentage of change (Median)
2400mg/Day SPN-804-49.15
1200mg/Day SPN-804-35.30
Placebo-32.90

[back to top]

Cmax - Maximum Observed Concentration - Oxcarbazepine in Plasma

Bioequivalence based on Cmax (NCT00849797)
Timeframe: Blood samples collected over 48 hour period

Interventionng/mL (Mean)
Oxcarbazepine3537.63
Trileptal®3820.31

[back to top]

Cmax - 10-hydroxy-carbazepine in Plasma

Informational Purposes Only (NCT00849797)
Timeframe: Blood samples collected over 48 hour period

Interventionng/mL (Mean)
Oxcarbazepine9349.83
Trileptal9517.52

[back to top]

AUC0-t - 10-Hydroxy-Carbazepine Metabolite

Informational Purposes Only (NCT00849797)
Timeframe: Blood samples collected over 48 hour period

Interventionng*h/mL (Mean)
Oxcarbazepine179002.40
Trileptal®177979.76

[back to top]

AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Oxcarbazepine

Bioequivalence based on AUC0-inf (NCT00849797)
Timeframe: Blood samples collected over 48 hour period

Interventionng*h/mL (Mean)
Oxcarbazepine9679.79
Trileptal®9772.18

[back to top]

AUC0-inf - 10-Hydroxy-Carbazepine Metabolite

Informational Purposes Only (NCT00849797)
Timeframe: Blood samples collected over 48 hour period

Interventionng*h/mL (Mean)
Oxcarbazepine197864.34
Trileptal®196607.20

[back to top]

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Oxcarbazepine

Bioequivalence based on AUC0-t (NCT00849797)
Timeframe: Blood samples collected over 48 hour period

Interventionng*h/mL (Mean)
Oxcarbazepine9445.55
Trileptal®9539.53

[back to top]

AUC0-inf - 10-hydroxy-carbazepine Metabolite

Results of Metabolite for informational purposes only (NCT00850174)
Timeframe: Blood samples collected over 48 hour period

Interventionng*h/mL (Mean)
Oxcarbazepine173770
Trileptal®174424

[back to top]

AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Oxcarbazepine

Bioequivalence based on AUC0-inf (NCT00850174)
Timeframe: Blood samples collected over 48 hour period

Interventionng*h/mL (Mean)
Oxcarbazepine5873.1
Trileptal®5711.7

[back to top]

AUC0-t - 10-hydroxy-carbazepine Metabolite

Results of metabolite for informational purposes only (NCT00850174)
Timeframe: Blood samples collected over 48 hour period

Interventionng*h/mL (Mean)
Oxcarbazepine157372
Trileptal®157542

[back to top]

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Oxcarbazepine

Bioequivalence based on AUC0-t (NCT00850174)
Timeframe: Blood samples collected over 48 hour period

Interventionng*h/mL (Mean)
Oxcarbazepine5309.5
Trileptal®5176.8

[back to top]

Cmax - 10-hydroxy-carbazepine in Plasma

Results of Metabolite for Informational Purposes Only (NCT00850174)
Timeframe: Blood samples collected over 48 hour period

Interventionng/mL (Mean)
Oxcarbazepine7119
Trileptal®7004

[back to top]

Cmax - Maximum Observed Concentration - Oxcarbazepine in Plasma

Bioequivalence based on Cmax (NCT00850174)
Timeframe: Blood samples collected over 48 hour period

Interventionng/mL (Mean)
Oxcarbazepine1630.3
Trileptal®1620.2

[back to top]

Cmax - Maximum Plasma Concentration in Plasma and Cerebral Spinal Fluid

Cmax - Maximum plasma concentration CSF - Cerebral Spinal Fluid Oxcarbazepine, BIA 2-194 and BIA 2-195 are active metabolites of Eslicarbazepine Acetate. (NCT00900237)
Timeframe: Day 9 - Pre-dose; 0.5h; 1h; 1.5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h; 24h

,
Interventionng/mL (Mean)
Cmax (BIA 2-194) plasmaCmax (BIA 2-195) plasmaCmax (Oxcarbazepine) plasmaCmax (BIA 2-194) CSFCmax (BIA 2-195) CSFCmax (Oxcarbazepine) CSF
Eslicarbazepine Acetate23932886245755953893.2
Oxcarbazepine161624039199075662146448

[back to top]

AUC0-t AUC From Time Zero to the Last Sampling Time

AUC0-t - area under the concentration versus time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the limit of quantification CSF - cerebrospinal fluid Oxcarbazepine, BIA 2-194 and BIA 2-195 are active metabolites of Eslicarbazepine Acetate. (NCT00900237)
Timeframe: Day 9 - Pre-dose; 0.5h; 1h; 1.5h; 2h; 3h; 4h; 6h; 8h; 12h; 16h; 24h

,
Interventionng.h/mL (Mean)
AUC0-t (BIA 2-194) plasmaAUC0-t (BIA 2-195) plasmaAUC0-t (Oxcarbazepine) plasmaAUC0-t (BIA 2-194) CSFAUC0-t (BIA 2-195) CSFAUC0-t (Oxcarbazepine) CSF
Eslicarbazepine Acetate340123187433377154509117911522
Oxcarbazepine16472639034713586187239962485

[back to top]

Percent Change in Seizure Rate

Measured as change from baseline to end of study (NCT00908349)
Timeframe: one year

Interventionpercentage of change in seizure rate (Median)
Oxcarbazepine XR-26.3

[back to top]

Average Annualized Costs

Average annualized overall healthcare costs and epilepsy-related healthcare costs were calculated for each treatment group. Epilepsy-related costs were those with a code for epilepsy. ED, Emergency Department; AMC, All Medical Costs; Ep Rel, Epilepsy Related. United States dollars were consumer price index adjusted for 2009. (NCT01390909)
Timeframe: 1 year

,,,,,,,
InterventionUnited States dollars (Mean)
AEDsNon-AEDsHospitalizations; AMCED Visits; AMCOutpatient Visits; AMCNeurology Visits; AMCOther Healthcare Services; AMCHospitalizations; Ep RelED Visits; Ep RelOutpatient Visits; Ep RelNeurology Visits; Ep RelOther Healthcare Costs; Ep RelTotal Healthcare Costs; AMC
Medicaid, Intermediate1050480135132421804522342817024624833127334839
Medicaid, Uncontrolled13575725704142124668622113413511146959147539123
Medicaid, Uncontrolled, Subgroup13525615690240024168622022410210946760150238708
Medicaid, Well Controlled46236579589712582123202NANA68975429635
Private, Intermediate12993883585825457804426452413394791654217719
Private, Uncontrolled171345871235760357715661026764615370223710226057
Private, Uncontrolled, Subgroup169744971130858657575561008670015270323510324853
Private, Well Controlled63930961697763061175436NANA17968179005

[back to top]

Time to the First Seizure Defined as the Time From the First Dose of Medication to the Occurrence of the First Seizure During the 48 Weeks Treatment Period

(NCT01498822)
Timeframe: From Week 2 to Week 50 (During Treatment Period )

Interventionmonths (Median)
Full Analysis Set (LEV Treated Subjects)7.556
Full Analysis Set (OXC Treated Subjects)NA

[back to top]

Percentage of Subjects With a Treatment Failure

Treatment failure is defined as (1) Dropout due to related intolerable adverse event, lack of efficacy or need for addition of another Antiepileptic Drug (AED), or (2) need of a 1-step down-Titration, within 50 weeks from the first dose of study medication. (NCT01498822)
Timeframe: Week 0 (First Dose) to Week 50

Interventionpercentage of subjects (Number)
Per Protocol Set (LEV Treated Subjects)12.7
Per Protocol Set (OXC Treated Subjects)23.4

[back to top]

Percentage of Subjects Who Achieved Seizure Freedom for 24 Consecutive Weeks During the 48 Weeks Treatment Period at Any Time

24-week Seizure Freedom (rate) defined as the number and percentage of subjects who achieved seizure freedom for 24 consecutive weeks during the Treatment Period at any time (NCT01498822)
Timeframe: From Week 2 to Week 50 (During Treatment Period )

Interventionpercentage of subjects (Number)
Full Analysis Set (LEV Treated Subjects)53.8
Full Analysis Set (OXC Treated Subjects)58.5

[back to top]

Percentage of Subjects Who Achieved Seizure Freedom During the 48 Weeks Treatment Period

48-week Seizure Freedom (rate) defined as the number and percentage of subjects who achieved seizure freedom during the Treatment Period (NCT01498822)
Timeframe: From Week 2 to Week 50 (During Treatment Period )

Interventionpercentage of subjects (Number)
Full Analysis Set (LEV Treated Subjects)34.7
Full Analysis Set (OXC Treated Subjects)40.9

[back to top]

Total of Subjects Reporting at Least One Adverse Event

Monitoring of Adverse Events throughout the study: Safety was evaluated from the number of reported adverse events (AEs) by patient (NCT01678976)
Timeframe: 4 weeks

,
Interventionsubjects reporting at least 1 AE (Number)
All treatment-emergent AEsPossibly related to treatment AEs
BIA 2-09365
Oxcarbazepine64

[back to top]

Maximum Drug Concentration (Cmax)

Maximum observed plasma concentration (Cmax) was acessed for BIA 2-093 metabolites (BIA 2-194; BIA 2-195) and Oxcarbazepine. (NCT01678976)
Timeframe: at pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 hours post-dose

,
Interventionng/mL (Mean)
Cmax (BIA 2-194)Cmax (BIA 2-195)Cmax (Oxcarbazepine)
BIA 2-093 900 mg od15753428140
Oxcarbazepine 900 mg od597817081268

[back to top]

Area Under the Plasma Concentration Versus Time Curve (AUC)

Area under the plasma concentration versus time curve (AUC) to last measurable time point (AUC0-t) was acessed for BIA 2-093 metabolites (BIA 2-194; BIA 2-195) and Oxcarbazepine. (NCT01678976)
Timeframe: at pre-dose, ½, 1, 1½, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 hours post-dose

,
Interventionng*h/mL (Mean)
AUC0-t (BIA 2-194)AUC0-t (BIA 2-195)AUC0-t (Oxcarbazepine)
BIA 2-093 900 mg od299065138771821
Oxcarbazepine 900 mg od214433491246549

[back to top]

AUC - Area Under the Plasma Concentration Versus Time Curve

"AUC - Area Under the Plasma Concentration Versus Time Curve for BIA 2-093 metabolites:~BIA 2-194 BIA 2-195 Oxcarbazepine" (NCT01679002)
Timeframe: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 h post-dose

,,
Interventionng*h/mL (Mean)
AUC0-t (BIA 2-194)AUC0-t (BIA 2-195)AUC0-t (Oxcarbazepine)
BIA 2-093 450 mg Bid283014190912699
BIA 2-093 900 mg od381601201643238
Oxcarbazepine 450 mg Bid268376488415196

[back to top]

Number of of Subjects Reporting at Least One Adverse Event

Number of of subjects reporting at least one adverse event. (NCT01679002)
Timeframe: 8 weeks

InterventionNumber of of subjects reporting at least (Number)
BIA 2-093 900 mg od9
BIA 2-093 450 mg Bid10
Oxcarbazepine 450 mg Bid11

[back to top]

Cmax - Maximum Observed Plasma Drug Concentration

"Cmax - maximum observed plasma drug concentration for BIA 2-093 metabolites:~BIA 2-194 BIA 2-195 Oxcarbazepine" (NCT01679002)
Timeframe: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72 and 96 h post-dose

,,
Interventionng/mL (Mean)
Cmax (BIA 2-194)Cmax (BIA 2-195)Cmax (Oxcarbazepine)
BIA 2-093 450 mg Bid16667702182
BIA 2-093 900 mg od22210685208
Oxcarbazepine 450 mg Bid1219524811080

[back to top]

Wechsler Intelligence Scale for Children-IV Processing Speed

Coding and Symbol Search subtests from the Wechsler Intelligence Scale for Children (WISC)-IV are measures of processing speed and combine to form the Processing Speed Index. Processing speed refers to how quickly the child understands and responds to information. Coding presents children with a row of boxes containing a numeral in the top line and a symbol in the bottom line with the task of copying the symbol corresponding to each numeral as quickly as possible in 120 seconds. In Symbol Search, children are given rows of symbols and target symbols and are asked to mark whether or not the target symbols appear in each row as quickly as possible during 120 seconds. Composite scores compare the test-taker to peers with a mean score of 100 and a standard deviation of 15. Possible scores range from 40 to 160 with higher scores indicating increased processing speeds. Scores between 85 and 115 are considered average, with 2/3 of test takers falling between these values. (NCT01891890)
Timeframe: Baseline, Month 3, Month 6

,,
Interventionunits on a scale (Mean)
BaselineAfter 3 months of treatmentAfter 6 months of treatment
Lamotrigine87.895.797.3
Levetiracetam102.196.9102.6
Oxcarbazepine97.990.4101.22

[back to top]

Pediatric Neuro-QOL Score

The Pediatric Neuro-QOL is a Quality of Life instrument developed in conjunction with NIH with a pediatric specific form utilized in this protocol. Pediatric Neuro-QOL assesses the domains of Anger, Anxiety, Cognition, Depression, Fatigue, Pain, Social Relations, and Stigma. Each domain has 8 to 10 items and respondents indicate how often they experienced feelings and circumstances related to each domain on a scale of 1 to 5 (such as 1=never, 2=almost never, 3=sometimes, 4=often, 5=almost always). Higher values indicate increased difficulty for most of the scales but this pattern is reversed for two of the domains. Raw scores are rescaled to standardized scores with a mean of 50 and a standard deviation of 10. Higher values for the standardized scores indicate more problematic characteristics while scores below 50 indicate that the child is experiencing less trouble in the domains measured by the Pediatric Neuro-QOL. (NCT01891890)
Timeframe: Baseline, Month 6

,,
Interventiont-scores (Mean)
BaselineAfter 6 months of treatment
Lamotrigine37.036.7
Levetiracetam38.836.9
Oxcarbazepine39.935.2

[back to top]

Affective Reactivity Scale

"The Affective Reactivity Scale is a 7-item survey completed by the child participants which asks questions concerning their level of agreement with statements about anger and irritability. Respondents select between not true (scored as 0), somewhat true (scored as 1), and certainly true (scored as 2). Total scores range from 0 to 14 with higher values indicating increased feelings of annoyance and anger." (NCT01891890)
Timeframe: Baseline, Month 3, Month 6

,,
Interventionunits on a scale (Mean)
BaselineAfter 3 months of treatmentAfter 6 months of treatment
Lamotrigine9.28.88.8
Levetiracetam8.610.310.3
Oxcarbazepine8.68.58.2

[back to top]

Child Behavior Checklist

The Child Behavior Checklist is a measure of specific behavioral and emotional problems are rated by the child's parent or guardian. The Child Behavior Checklist examines three domains (Social Functioning, Mood and Anxiety Symptoms, and Externalizing Symptoms) by assessing 118 problem items that describe specific behavioral and emotional problems. Respondents indicate how accurately the statements describe the child by selecting from options on a 3-point Likert-type scale (0=Not True, 1= Somewhat or Sometimes True, or 2=Very True or Often True). Total raw scores are converted to t-scores with a mean of 50 and standard deviation of 10. A t-score of 67 or greater is considered to be in the clinical range for problematic behavior. (NCT01891890)
Timeframe: Baseline, Month 6

,,
Interventiont-scores (Mean)
BaselineAfter 6 months of treatment
Lamotrigine37.637.5
Levetiracetam38.233.3
Oxcarbazepine39.836.7

[back to top]

Conners' Continuous Performance Test II (CPT-II) Confidence Index

"The Conners' Continuous Performance Test II (CPT-II) is a measure of sustained attention. Letters are individually presented on a computer screen, and participants are instructed to press the space bar when they are presented with any letter except the letter X. For children younger than 6 years of age at enrollment, the Kiddie CPT will be used in which the child is instructed to press the space bar every time the ball appears on the screen. The outcome measure is a confidence index representing the probability that the respondent has a clinically relevant problem in sustained attention. Possible scores range from 0 to 100. Scores between 40 and 60 are considered inconclusive while scores above 60 indicate that the child exhibits inattentiveness." (NCT01891890)
Timeframe: Baseline, Month 6

,,
InterventionConfidence Index (Mean)
BaselineAfter 6 months of treatment
Lamotrigine58.458.1
Levetiracetam56.954.0
Oxcarbazepine56.754.2

[back to top]

Grooved Pegboard

The Grooved Pegboard assesses fine motor speed and dexterity. The participant fits keyhole-shaped pegs into similarly shaped holes on a square board. The pegs, which have an edge along one side, must be rotated to match the holes before they can be inserted. The scores represent the number of seconds it took for the participant to correctly insert the pegs into the require number of grooves, using their dominant hand. (NCT01891890)
Timeframe: Baseline, Month 6

,,
InterventionSeconds (Mean)
BaselineAfter 6 months of treatment
Lamotrigine99.990.3
Levetiracetam114.294.9
Oxcarbazepine96.390.1

[back to top]

Parenting Stress Inventory Short Form (PSI-4-SF)

The Parenting Stress Inventory-4-Short Form is a 36 item questionnaire, completed by the parent/guardian, designed to evaluate parenting and family characteristics based upon child characteristics (behavioral and emotional problems), parent characteristics, and situational/demographic life stress. Respondents indicate the degree to which they agree with a variety of statements by selecting 1=strongly agree, 2=agree, 3=not sure, 4=disagree, or 5=strongly disagree. Raw scores range from 36 to 180 and higher scores are associated with higher parental stress. (NCT01891890)
Timeframe: Baseline, Month 6

,,
Interventionunits on a scale (Mean)
BaselineAfter 6 months of treatment
Lamotrigine138.2147.4
Levetiracetam143.9146.8
Oxcarbazepine138.3137.6

[back to top]

Pediatric Inventory for Parents

"The Pediatric Inventory for Parents consists of 42 items involving communication, medical care, emotional disturbance, and change in role function. Parents respond to a list of difficult events (such as difficulty sleeping) that are often experienced by parents of children who are seriously ill. Parents indicated how frequently an event occurred by selecting 1=Never, 2=Rarely, 3=Sometimes, 4=Often, or 5=Very often. Raw score values range from 4 to 210 with higher scores indicating increased frequency of difficult events." (NCT01891890)
Timeframe: Baseline, Month 6

,,
Interventionunits on a scale (Mean)
BaselineAfter 6 months of treatment
Lamotrigine93.074.2
Levetiracetam91.174.8
Oxcarbazepine98.476.5

[back to top]

Story Memory

"Story Memory will be measured at baseline with the Children's Memory Scale (CMS) and then with the Wide Range Assessment of Memory and Learning-2 (WRAML-2) at the 6 month follow up visit. Two different tests are used to avoid practice effects in memory assessment associated with repeated assessments using the same stimulus material. The Story Memory sub-test of the CMS and the WRAML-2 Story Memory are measures of prose passage recall. Stories are read to the subject for recall, with different stories presented based upon participant age. Scores are converted to percentile ranks for both measurements of story memory. Possible scores can fall between the 1st and 99th percentile and higher values indicate better performance with story recall. Values between the 9th and 25 percentiles are considered low average, values between the 25th and 75th percentiles are average, while values between the 75th and 91st percentile are high average." (NCT01891890)
Timeframe: Baseline, Month 6

,,
Interventionpercentiles (Mean)
Baseline (CMS)After 6 months of treatment (WRAML-2)
Lamotrigine29.623.1
Levetiracetam29.426.5
Oxcarbazepine31.226.1

[back to top]

Symbol Digit Modalities Test

Symbol Digit Modalities Test (SDMT) is a test of graphomotor speed using numbers as the response rather than copying symbols, and is timed at 90 seconds. The SDMT is designed for people who are 8 years of age and older and detects brain dysfunction as well as measures function over time. Possible total scores range from 0 to 110; where 110 indicates that all values were entered within the 90 second limit. An increase between initial and retest scores indicates that the respondent is correctly matching numbers to symbols at a faster speed. The SDMT was administered at the Month 3 and Month 6 visits for this study. (NCT01891890)
Timeframe: Month 3, Month 6

,,
Interventionnumber of correct responses (Mean)
After 3 months of treatmentAfter 6 months of treatment
Lamotrigine25.926.4
Levetiracetam23.028.3
Oxcarbazepine28.530.4

[back to top]

The Number of Participants With a Positive Response on the Columbia-Suicide Severity Rating Scale (C-SSRS)

"Suicidal behaviors and suicidal ideation were assessed through an interview using the Columbia-Suicide Severity Rating Scale (C-SSRS). The C-SSRS guides interviewers to ask a series of simple questions in order to identify people at risk for suicide, as well as the severity and urgency of suicidal thoughts and behaviors. The Children's Baseline/Screening C-SSRS was used at the initial study visit while the Children's Since Last Visit C-SSRS was used for subsequent study visits. Any responses of yes to the C-SSRS questions are considered a positive response, indicating that the participant is experiencing thoughts of suicide or has exhibited suicidal behaviors." (NCT01891890)
Timeframe: Baseline, Month 3, Month 6

,,
InterventionParticipants (Count of Participants)
BaselineAfter 3 months of treatmentAfter 6 months of treatment
Lamotrigine000
Levetiracetam000
Oxcarbazepine000

[back to top]

Change in Serum Brain Derived Neurotrophic Factor (BDNF)

Serum BDNF was estimated by ELISA using human BDNF ELISA kit from Boster Biological Technology Co. Ltd., Pleasanton, CA. (NCT02456896)
Timeframe: Baseline and 4 weeks

Interventionpg/ml (Mean)
Healthy Control23.1
Oxcarbazepine90.7

[back to top]

Correlation Between Young Mania Rating Scale (YMRS) and Serum Brain Derived Neurotrophic Factor (BDNF)

"The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania.~Spearman's rank correlation coefficient (Spearman's ρ) was calculated for measuring correlation between YMRS score and serum BDNF." (NCT02456896)
Timeframe: At baseline

InterventionSpearman's ρ (Number)
Healthy Control-0.59
Oxcarbazepine-0.59

[back to top]

Mean Cmax_ss (Test vs. Reference)

Average maximum drug plasma concentration; (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.

,,,,,,
Interventionmicrog/mL (Mean)
Test ProductReference Product
Carbamazepine ER Capsule10.959.91
Carbamazepine ER Tablet10.0010.6
Lamotrigine ER Tablet6.246.903333333
Levetiracetam ER Tablet31.0528.04
Levetiracetam IR Tablet71.0233333369.29333333
Topiramate Tablet9.8749.646
Zonisamide Capsule12.2911.68

[back to top]

Mean AUC0-last_ss (Test vs. Reference)

Average AUC (area under the drug plasma curve. (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.

,,,,,,
Interventionmicro/mL/hr (Mean)
Test ProductReference Product
Carbamazepine ER Capsule114.96106.45
Carbamazepine ER Tablet104.6115.16
Lamotrigine ER Tablet62.7666666767.19333333
Levetiracetam ER Tablet260.3262.305
Levetiracetam IR Tablet419.97445.2
Topiramate Tablet92.88494.456
Zonisamide Capsule233.16226.14

[back to top]

Number of Adverse Events

summed for each anti-epileptic drug from when taking brand and generic. (NCT02707965)
Timeframe: Through the approximately 2 week period when the treatment is given.

Interventionevents (Number)
Topiramate29
Lamotrigine ER9
Levetiracetam IR17
Levetiracetam ER4
Carbamazepine ER Capsule15
Zonisamide6
Carbamazepine ER Tablet10
Valproic Acid10

[back to top]

Number of Seizures Reported

Number of seizures reported in all groups (NCT02707965)
Timeframe: Through the approximately 2 week period when the treatment is given.

,,,,,,,,
InterventionNumber of Seizures (Number)
Reference ProductTest (Generic)
Carbamazepine ER Capsule31
Carbamazepine ER Tablet00
Lamotrigine ER Tablet Group4425
Lamotrigine IR Tablet Group00
Levetiracetam ER Tablet Group4272
Levetiracetam IR Tablet Group165
Topiramate Tablet Group95
Valproic Acid ER Tablet Group120
Zonisamide Capsule Group00

[back to top]

Mean Cmin_ss (Test vs. Reference)

Average minimum drug plasma concentration (Cmin); (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.

,,,,,,
Interventionmicrog/mL (Mean)
Test ProductReference Product
Carbamazepine ER Capsule8.567.66
Carbamazepine ER Tablet7.377.97
Lamotrigine ER Tablet4.0533333334.21
Levetiracetam ER Tablet12.60514.395
Levetiracetam IR Tablet15.4533333317.45666667
Topiramate Tablet6.3266.53
Zonisamide Capsule8.468.34

[back to top]

Percentage of Participants With at Least One Serious Adverse Event (SAE) During the Study

A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in patient hospitalization or prolongation of existing hospitalization, was a congenital anomaly or birth defect, was an infection that requires treatment parenteral antibiotics or other important medical events which based on medical or scientific judgement could jeopardize the patients, or could require medical or surgical intervention to prevent any of the above. (NCT03695094)
Timeframe: From screening (Day -28 to Day -2) up to end of study (EOS) visit day 20 (+/-1)

Interventionpercentage of participants (Number)
Group 1 (Inducers) (FAS)0
Group 2 (Neutral [Control]) (FAS)0

[back to top]

The Maximum Observed Plasma Concentration (Cmax) of Padsevonil (PSL) During the Study

The Cmax for Padsevonil in plasma was expressed in nanograms per milliliter (ng/mL). (NCT03695094)
Timeframe: Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose

Interventionng/mL (Least Squares Mean)
Group 1 (Inducers) (PK-PPS)1210
Group 2 (Neutral [Control]) (PK-PPS)1670

[back to top]

Trough Plasma Concentration of Mono Hydroxy Derivate (MHD) in the Inducers Group Before, During and After Dosing to Steady State With PSL

"The trough plasma concentration of MHD with PSL was expressed in micrograms per milliliter (µg/mL).~Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged)." (NCT03695094)
Timeframe: Trough plasma samples were taken prior to the morning dose of OXC on Day -1, Day 1 through Day 20 (+/-1)

Interventionµg/mL (Geometric Mean)
Day 1Day 2Day 3Day 4Day 5Day 6Day 7Day 8Day 9Day 10Day 11Day 12Day 13
Group 1 (Inducers) (PK-PPS)14.914.014.915.515.215.415.416.315.415.515.413.811.3

[back to top]

The Time to Reach Maximum Concentration (Tmax) for UCB1431322-000 During the Study

The tmax for UCB1431322-000 in plasma was expressed in hours (hr). (NCT03695094)
Timeframe: Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose

Interventionhr (Median)
Group 1 (Inducers) (PK-PPS)3.500
Group 2 (Neutral [Control]) (PK-PPS)3.500

[back to top]

The Time to Reach Maximum Concentration (Tmax) for UCB1447499-000 During the Study

The tmax for UCB1447499-000 in plasma was expressed in hr. (NCT03695094)
Timeframe: Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose

Interventionhr (Median)
Group 1 (Inducers) (PK-PPS)2.000
Group 2 (Neutral [Control]) (PK-PPS)2.000

[back to top]

The Time to Reach Maximum Concentration (Tmax) for Padsevonil During the Study

The tmax for Padsevonil in plasma was expressed in hours (hr). (NCT03695094)
Timeframe: Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose

Interventionhr (Median)
Group 1 (Inducers) (PK-PPS)1.500
Group 2 (Neutral [Control]) (PK-PPS)2.000

[back to top]

The Ratio of PSL Metabolite UCB1447499-000 to PSL Based on the Area Under the Curve (AUCtau)

Metabolite-to-Parent Ratios were corrected for differences in molecular weight. Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged). (NCT03695094)
Timeframe: Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose

Interventionratio (Geometric Mean)
Group 1 (Inducers) (PK-PPS)0.3492
Group 2 (Neutral [Control]) (PK-PPS)0.2011

[back to top]

The Ratio of PSL Metabolite UCB1431322-000 to PSL Based on the Area Under the Curve (AUCtau) During the Study

Metabolite-to-Parent Ratios were corrected for differences in molecular weight. Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged). (NCT03695094)
Timeframe: Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose

Interventionratio (Geometric Mean)
Group 1 (Inducers) (PK-PPS)2.283
Group 2 (Neutral [Control]) (PK-PPS)1.386

[back to top]

Percentage of Participants With at Least One Adverse Event (AE) During the Study

An AE was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. (NCT03695094)
Timeframe: From screening (Day -28 to Day -2) up to end of study (EOS) visit day 20 (+/-1)

Interventionpercentage of participants (Number)
Group 1 (Inducers) (FAS)100
Group 2 (Neutral [Control]) (FAS)100

[back to top]

The Maximum Observed Plasma Concentration (Cmax) for UCB1447499-000 During the Study

The Cmax for UCB1447499-000 in plasma was expressed in ng/mL. Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged). (NCT03695094)
Timeframe: Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose

Interventionng/mL (Geometric Mean)
Group 1 (Inducers) (PK-PPS)380.1
Group 2 (Neutral [Control]) (PK-PPS)307.2

[back to top]

The Maximum Observed Plasma Concentration (Cmax) for UCB1431322-000 During the Study

"The Cmax for UCB1431322-000 in plasma was expressed in nanograms per milliliter (ng/mL).~Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged)." (NCT03695094)
Timeframe: Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose

Interventionng/mL (Geometric Mean)
Group 1 (Inducers) (PK-PPS)1753
Group 2 (Neutral [Control]) (PK-PPS)1700

[back to top]

The Area Under the Plasma Concentration Time Curve (AUCtau) Over a Dosing Interval for PSL

The AUCtau for Padsevonil in plasma was expressed in hours times nanograms per milliliter (hr*ng/mL). (NCT03695094)
Timeframe: Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose

Interventionhr*ng/mL (Least Squares Mean)
Group 1 (Inducers) (PK-PPS)5301
Group 2 (Neutral [Control]) (PK-PPS)8339

[back to top]

The Area Under the Curve (AUCtau) Over a Dosing Interval for UCB1447499-000 During the Study

The AUCtau for UCB1447499-000 in plasma was expressed in hr*ng/mL. Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged). (NCT03695094)
Timeframe: Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose

Interventionhr*ng/mL (Geometric Mean)
Group 1 (Inducers) (PK-PPS)1854
Group 2 (Neutral [Control]) (PK-PPS)1678

[back to top]

The Area Under the Curve (AUCtau) Over a Dosing Interval for UCB1431322-000 During the Study

"The AUCtau for UCB1431322-000 in plasma in was expressed in hours times nanograms per milliliter (hr*ng/mL).~Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged)." (NCT03695094)
Timeframe: Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose

Interventionhr*ng/mL (Geometric Mean)
Group 1 (Inducers) (PK-PPS)11720
Group 2 (Neutral [Control]) (PK-PPS)11200

[back to top]

The Apparent Total Plasma Clearance at Steady-state (CL/Fss) for PSL During the Study

The CL/Fss for Padsevonil in plasma was expressed in liters per hour (L/hr). Geometric Means and Coefficients of Variation (CVs) were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e. non-calculated and non-flagged). (NCT03695094)
Timeframe: Blood samples were taken on Day 1 through Day 12, prior to the morning dose of PSL, at Day 13 prior to unit discharge and at Day 8 at pre-defined time points up to 12 hours post-dose

InterventionL/hr (Geometric Mean)
Group 1 (Inducers) (PK-PPS)75.44
Group 2 (Neutral [Control]) (PK-PPS)47.94

[back to top]